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Morphine is the most prominent pharmacological treatment for moderate to severe pain in both 
acute and chronic paradigms.  However, morphine notoriously elicits a paradoxical state of 
increased pain sensitivity known as hyperalgesia that complicates its use in clinical application.  
Research over the past three decades has reported that morphine-induced hyperalgesia is dose- 
and sex-dependent, and likely involves the synchronous activity of several neural networks 
beyond the opioid system.  Whereas systemic, supraspinal, and spinal administration of 
morphine all cause hyperalgesia that is differentially reversible by N-methyl-D-aspartate receptor 
(NMDAR) antagonists or melanocortin-1 receptor (MC1R) antagonists, it is unknown as to 
whether or not these non-opioid systems that contribute to this state are located supraspinally or 
spinally.  The current studies were performed with the goal of elucidating the precise location of 
regulatory action of this sex- and dose- dependent state of morphine hyperalgesia. 
 
In all studies, outbred CD-1 male and female mice were pretreated with the general opioid 
receptor antagonist, naltrexone (NTX) 24 hours prior to morphine treatment.  All mice were 




high dose of morphine (40mg/kg/24h).  As noted previously, mice of both sexes were 
hyperalgesic by Day 4 of continuous infusion of either morphine dose, a state that persisted 
through Day 6 of infusion. The first series demonstrated that NMDAR and MC1R systems that 
mediate this morphine-induced hyperalgesic state are located supraspinally, as 
intracerebroventricular injections of MK-801 and MSG606, respectively successfully reversed 
hyperalgesia during a one-hour testing period. A second series of studies investigated possible 
involvement of spinal systems.  Whereas intrathecal MK-801 significantly reversed hyperalgesia 
in males at both doses, and females at the low morphine infusion dose, spinal administration of  
MSG606 significantly reduced hyperalgesia in females following continuous high dose morphine 
infusion.  This indicates that the sex-dependent mechanism involved in morphine-induced 
hyperalgesia is located supraspinally and spinally, and either locus can independently modulate 
female-typical hyperalgesia. 
 
A third series of studies investigated hormonally-regulated mechanisms involved in morphine-
induced hyperalgesia.  Ovariectomized females displayed male-typical patterns of hyperalgesia 
after i.c.v. and i.t. antagonist injection paradigms following continuous infusion of either dose of 
morphine on Day 4.  On Day 6, NMDAR and MC1R antagonist injections were preceded by an 
acute systemic progesterone injection in ovariectomized female mice, and intact male mice.  
Following continuous morphine infusion, ovariectomized females displayed male-typical 
patterns of hyperalgesic reversal.  However, following progesterone administration, hyperalgesia 
elicited by high doses of morphine was reversed by i.c.v. injection of MK-801 and MSG606 in 
both males and ovariectomized females.  Conversely, following i.t. injections the data show that 




exclusively used the NMDAR system to mediate hyperalgesia.  The current studies indicate that 
in terms of modulating morphine-induced hyperalgesia, there are both supraspinally- and 
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The use of opium, primarily for recreational purposes, has been documented as early as 3000 to 
2500 B.C.  During this time, period the Sumerians were amongst the first to cultivate poppies, 
naming them “hul gil” or “plant of joy”.  The Sumerians were also documented to have isolated 
opium from the seed capsules of poppies, giving it the name “gil”, meaning “joy”.  Around 1500 
B.C., descriptions of medicinal administration of opium surfaced; however, physicians at the 
time were hesitant to use such methods due to opium’s unpredictable potency.  By the thirteenth 
century A.D., the use of opium was believed to be widespread across Europe, and it is around 
this period that manuscripts describing abuse and addiction to the drug surfaced.  Despite the 
apparent negative side effects of opium, efforts to ban the substance were unsuccessful 
(Christup, 1997; Brownstein, 1993). 
 
Although the extensive use of and experimentation with opium over the previous millennia had 
already been cited, Friedrich Sertürner is credited with the discovery of the active ingredient in 
opium now known as morphine, in 1806.  Sertürner successfully isolated the alkaloid compound 
from the dried juice of the unripe seedpods of the poppy plant, and named the substance 
“morphium” after the god of dreams, Morpheus.  Subcutaneous intravenous administration of 
morphine for surgical procedures and the management of pain began in the 1850s; however, it 
was also becoming increasingly clear that morphine had negative and potentially harmful side 
effects such as addiction, respiratory depression, and analgesic tolerance which would require an 




imperative to discover either a natural or a synthetic substance that could offer the positive, pain 
relieving effects of morphine without the unwanted side effects.  Use of codeine, heroin, 
meperidine, and methadone all became common practice in the search for a safer, alternative 
opioid (Brownstein, 1993).  Nonetheless, morphine is still regarded as one of the most effective 
analgesics for treatment of both acute and chronic pain (Mao et al., 2002; Brownstein, 1993, Lee 
et al., 2011; Ossipov, Lai, King, Vanderah, Malan, et al., 2004).  In a never-ending effort to 
elucidate the precise pharmacokinetics and pharmacodynamics of morphine, studies within the 
last three decades have provided evidence that while morphine is a potent analgesic, it also 
produces a state of increased sensitivity to pain, or hyperalgesia (Woolf, 1981; Crain & Shen, 
2001; Vaughan & Connor, 2003; Chieng, Hallberg, Nyberg, & Christie, 2005; Galeotti, Stefano, 
Guarna, Biacnhi, & Ghelardini, 2006; van Dorp, et al., 2009).  This hyperalgesic state is 
seemingly evoked by both acute and continuous infusion doses of morphine (Juni, Klein, and 
Kest, 2006). 
 
Hyperalgesia is a puzzling side effect of morphine. While morphine is well known for its 
analgesic properties, the drug also produces a paradoxical state of heightened nociception after 
both acute and long-term use (Woolf, 1981; Crain & Shen, 2001; Vaughan & Connor, 2003; 
Chieng, Hallberg, Nyberg, & Christie, 2005; Galeotti, Stefano, Guarna, Biacnhi, & Ghelardini, 
2006; van Dorp, et al., 2009).  Hyperalgesia is defined as an increased sensitivity to pain as well 
as allodynia, which is pain evoked by a stimulus that is not under normal circumstances 
considered painful (Heger, Mair, Otter, Helwig, & Suttorp, 1999).  Such a phenomenon is 
usually evident following administration of titrated doses of opioids, which is almost always 




morphine is particularly infamous for its likelihood to evoke hyperalgesia, other short-acting 
opiates such as fentanyl (Waxman, Arout, Caldwell, Dahan, & Kest, 2009) and remifentanil 
(Cooper, Lindsay, Ryall, Kokri, Eldabe, & Lear, 1997; Guignard, Bossard, Coste, Sessler, 
Lebrault, et al., 2000; Hansen, Duedahl, Romsing, Hilsted, & Dahl, 2005) also induce the same 
phenomenon.  While hyperalgesia can be predictably elicited in animals (Woolf, 1981; Mao et 
al., 1994; Ossipov, Lai, Vanderah, & Porreca, 2003; Waxman et al., 2009; Juni et al. 2010; 
Waxman et al., 2010), in humans this paradoxical state appears to be less predictable and a quite 
serious complication of clinical opioid treatment (Compton, 2008; De Conno et al., 1991; 
Ossipov et al., 2004; Sjøgren et al., 1994; Sjøgren et al., 1998). 
 
There are several prominent hypotheses of opioid-induced hyperalgesia.  One common theory of 
hyperalgesia is that this state is a causative factor in analgesic tolerance.  Specifically, the 
increased pain sensitivity that one experiences after opioid treatment causes the need for 
increasing doses of opioids, thus indicative of tolerance (Vanderah et al., 2001).  A second 
popular hypothesis is that hyperalgesia is an adaptive response that serves as a systems-level 
opponent process in response to morphine analgesia after prolonged treatment.  That is, as the 
body is always striving to maintain homeostasis, one’s natural response to exogenously elicited 
analgesia is to create an opposing state of hyperalgesia in attempt to regain physiological 
equilibrium (Simonnet & Rivat, 2003; Ossipov et al., 2003; Ossipov et al., 2004; Li, 2012).  A 
third theory that is gaining popularity is that hyperalgesia is a result of a glial cell-regulated 
immune response (Hutchinson et al., 2009; Lewis et al., 2010; Watkins, Wiertelak, Goehler, 
Mooney-Heiberger, Martinez, et al., 1994; Watkins, Hutchinson, Rice, & Maier, 2009). With 




example, Crain & Shen (1990, 2000) review evidence suggesting that although opioids are 
reliably inhibitory, they can also exert excitatory effects on sensory neurons to produce the 
aversive side effects of opioids.  Furthermore, it is postulated that hyperalgesia is served by a 
cellular mechanism by which opioids sensitize spinal neurons, thereby increasing pain 
sensitivity.  Specifically, while opioids are thought to produce analgesia via action at inhibitory 
Gi/Go-coupled opioid receptors, Gs-coupled excitatory opioid receptor activity could be the 
cellular mechanism responsible for hyperalgesia.  Specifically, Wu et al. (1998) report that 
opioid receptors can switch between Gi/Go-coupled and Gs-coupled receptors following 
alterations in GM1 ganglioside, a compound that affects neuronal plasticity as well as the 
activity of neurotrophins. 
 
At the receptor level, morphine hyperalgesia has been demonstrated to be dose- and sex- 
dependent. For example, infusing lower morphine doses produces no analgesia, but evokes 
hyperalgesia within hours of administration.  This hyperalgesia resolves within one week in 
males, but persists for minimally 14 days in females.  Alternatively, higher continuous infusion 
doses of morphine cause analgesia that lasts approximately two to three days, followed by a 
hyperalgesic period that persists through day 11 in both males and females (Juni, Klein, & Kest, 
2006; Waxman et al., 2010).  Additionally, there is no cross-adaptation between high and low 
morphine doses (Juni et al., 2006).  Furthermore, whereas the N-Methyl-D-aspartate receptor 
(NMDAR) antagonist MK-801 can reverse morphine hyperalgesia in mice of both sexes 
following the low infusion dose, it does so only in males – not females – undergoing continuous 
infusion of the larger dose (Juni et al., 2008; Waxman et al., 2010).  Furthermore, ovariectomy in 




while estrogen replacement in these same females restores female-typical patterns (Juni et al., 
2008).  This suggests that females possess functional male-typical hyperalgesic mechanisms, but 
their use is prevented by to circulating ovarian hormones (Juni et al., 2008).  The melanocortin-1 
receptor (MC1R) antagonist MSG606 has been found to reverse hyperalgesia in exclusively 
females infused with a high dose of morphine, indicative of minimally two sexually dimorphic, 
dose-dependent hyperalgesic systems (Juni, Cai, Stankova, Waxman, Arout, et al., 2010). 
 
The mechanisms mediating opioid hyperalgesia are numerous and complex.  Although a 
majority of the literature has investigated chronic morphine treatment, the sites of action and 
mechanisms underlying sex- and dose-dependent chronic morphine-induced hyperalgesia still 
remain nebulous.  Therefore, a thorough analysis of hyperalgesia during continuous morphine 
infusion in both supraspinal and spinal circuits of males and females is necessary to contribute to 
our current understanding of the molecular mechanisms, organismic factors, and neurocircuitry 
underlying this phenomenon. 
 
In order to provide a context for the proposed series of studies, the following section will provide 
a review of the relevant literature and previous findings. The topics covered will include: 
1) Opioid Pharmacology 
a. Discovery of the opioid receptors 
b. Opioid receptor neuroanatomical distribution 
c. Opioid receptor modulation of nociception 
2) Prevalence of Opioid-Induced Hyperalgesia 




b. Animal Studies 
3) Mechanisms of Opioid-Induced Hyperalgesia 
a. Opioid-related mechanisms 
b. Cellular sensitization 
c. Morphine metabolites 
4) Opioid-Induced Hyperalgesia and the N-Methyl-D-aspartate Receptor (NMDAR) System 
a. NMDAR distribution 
b. NMDAR-mediated opioid hyperalgesia 
c. Role of glutamate transporters in opioid-induced hyperalgesia 
5) Opioid-Induced Hyperalgesia and the Melanocortin-1 Receptor (MC1R) System 
a. MC1R distribution 
b. Sex differences in opioid-induced analgesia and hyperalgesia 
 
The final section of the introduction will provide the rationale for the specific studies and general 





1. Opioid Pharmacology 
1a.   Discovery of the opioid receptors.  In the 1940s, scientists began rigorous research on the 
effects that various agonists and antagonists have on the nervous system.  It was found that 
certain compounds such as nalorphine and naloxone had diverse pharmacokinetic effects on 
opioid activities and responses.  For example, being a mixed agonist-antagonist, nalorphine was 
found to block the effects of morphine while also emitting its own analgesic potency 
(Brownstein, 1993).  However, the pure opioid antagonist naloxone has been found to only 
abolish the analgesic effects of morphine and thus quickly induce withdrawal, while not causing 
any effects on its own (Brownstein, 1993).  Studies using agonists and antagonists have been 
immensely useful in defining the pharmacokinetics and pharmacodynamics of morphine, such 
that their usage led to the discovery of endogenous opioids.  In 1973, three independent groups 
of investigators concurrently reported the finding of endogenous receptors for opioids, referring 
mainly to the µ receptor (Pert & Snyder, 1973; Simon, 1973; Terenius, 1973).  It was then 
reasoned that if the human body has preexisting and naturally occurring receptors that respond to 
compounds not found in the body such as naloxone (Pert & Snyder, 1973), then there must be a 
compound of similar chemical structure that is produced within the body that is meant to bind 
these endogenous receptors.  Consequently, it was reasoned that this compound likely serves as 
the body’s natural pain reliever (Pert & Snyder, 1973). 
 
Such findings led to a distinction of two primary classes of opioid receptor ligands: opiates and 
opioids.  Consequently, this led to a distinction in terminology, as the terms “opiate” and 
“opioid” were and still are often used in a transposable manner. Scientifically speaking, the term 




somniferum, which therefore concerns the first two drugs that were found in these juices: 
morphine and codeine. The latter term “opioid” refers to all substances, whether endogenous or 
exogenous, which bind to opioid receptors. Exogenous opioids can be natural (i.e. morphine), 
semisynthetic (i.e. heroin), or synthetic (i.e. fentanyl).  In addition to the discovery of the 
aforementioned exogenous opioid substances, four classes of endogenous opioid peptides that 
bind to opioid receptors were also revealed by the early 1980s: endorphins, enkephalins, 
dynorphins, and deltorphins (Brownstein, 1993). 
 
Following the discovery of an endogenous opioid system, researchers sought to further 
characterize opioid receptors.  Martin et al. (1967) were amongst the first to suggest the 
existence of not one, but several opioid receptor subtypes after their extensive studies of the 
neurophysiological and behavioral effects of several opioid compounds (Brownstein, 1993).  
Through these studies, Martin and his colleagues observed three independent behavioral 
syndromes in response to three different opioid agonists.  Subsequently, three different receptors 
were named after the agonist that was first found to bind to each one: mu was named for its 
ability to bind morphine, kappa was named for ketocyclazocine, and sigma was named for SKF-
10,047.  Following this, the delta receptor was discovered and named for its differential binding 
of [Met5]enkephalin and β-endorphin against [3H][Leu5]enkephalin and [3H]naloxone (Lord, 
Waterfield, Hughes, & Kosterlitz, 1977; Waterfield, Leslie, Lord, Ling, & Kosterlitz, 1979; 
Waterfield, Lord, Hughes, & Kosterlitz, 1978, Brownstein, 1993).  Another receptor, termed the 
epsilon receptor, was proposed for a short time as an additional opioid receptor for its ability to 
bind β-endorphin.  However, ensuing advances in the ability to clone receptors as well as the 




(µ), which preferentially binds morphine; delta (δ), which primarily binds enkephalins and 
deltorphins, and kappa (κ), which preferentially binds benzomorphans and dynorphins 
(Brownstein, 1993; Mollereau, Parmentier, Mailleux, Butour, Moisand, et al., 1994; Ossipov et 
al., 2004).  More recently, an opioid-like receptor has been found and termed ORL1, and is now 
considered a fourth opioid receptor (Mollereau, Simons, Soularue, Liners, Vassart, et al., 1996).  
Interestingly, although ORL1 is both structurally and functionally similar to the other three 
opioid receptor subtypes, it does not bind typical opioid agonists or antagonists and has an 
endogenous ligand of nociceptin, or orphanin FQ. All four opioid receptors are classified as G 
protein-coupled receptors that activate the following G-proteins: Gi to inhibit adenylyl cyclase, 
Gk to stimulate K+ channels, and Go to inhibit Ca2+ channels (Mollereau et al., 1994).  The 
investigation into the existence of other opioid-like receptors and the validity of such receptors in 
the opioid system is still ongoing. 
 
1b.  Opioid receptor neuroanatomical distribution.  The anatomical distribution of the three 
main opioid receptors (µ, δ, and κ) varies rostrocaudally with each subtype (Gouardères, Cros, & 
Quirion, 1985).  Pert and Snyder (1973) first reported a concentration of opioid receptors in the 
nervous tissue of both the mammalian brain and the intestine of the guinea pig.  Distribution and 
anatomical localization of each of the opioid receptor subtypes has been investigated via in vitro 
autoradiography, radioligand binding, highly selective-ligand binding, in situ hybridization of 
mRNA for each receptor subtype, and immunohistochemistry (Ossipov et al., 2004).  In terms of 
spinal sites of action, opioid receptors are concentrated in lamina I, II, and III of the dorsal horn 
(the marginal zone, the substantia gelatinosa, and the nucleus proprius, respectively) and dorsal 




the principal spinal sites of action of morphine on the transmission of nociceptive signals (Besse 
et al., 1990).  Specifically, the µ-opioid receptor is highly concentrated and is the primary 
subtype in the outer laminae of the dorsal horn in the cervical to lumbosacral portion of the 
spinal cord, making up approximately 70% of opioid receptors found in this region (Quirion, 
1984).  The δ-opioid receptor is more diffusely distributed throughout the dorsal horn, 
accounting for approximately 23% of opioid receptors in the spinal cord, though it is found in 
dense concentrations in the outer laminae of the cervical and thoracic segments.  The κ-opioid 
receptor is present in the smallest foci of the three subtypes (approximately 7%), and is 
concentrated in the outer laminae of the dorsal horns of the lumbosacral region of the spinal 
cord.  It receives nociceptive inputs primarily from the viscera of the body (Quirion, Zajac, 
Morgat, & Roques, 1983; Quirion, 1984; Besse, Lombard, Zajac, Roques, & Besson, 1990; 
Besse, Lombard, & Besson, 1991; Ossipov et al., 2004). 
 
ORL1’s distribution is discrete yet widespread, as its transcripts are found in many areas of the 
central nervous system including the limbic system, hypothalamus, brainstem, and spinal cord.  
Additionally, ORL1 does not appear to have an affinity for any one particular area, making it 
likely that its functions are not be limited solely to pain transmission, which supports Mansour et 
al.’s (1987) earlier speculation of a more functionally diffuse opioid receptor (Mollereau et al., 
1994).  In addition to antinociceptive functions, ORL1 has displayed a role in other central 
functions such as emotions, regulation of neuroendocrine secretion and immune functioning, 
food intake, instinctive behaviors, spatial memory, and anxiety (Mollereau et al., 1994; 
Bertorelli, Corradini, Rafiq, Tupper, Calò, et al., 1999; Barlocco, Cignarella, Giardina, & Toma, 




investigation, lack reliability, and are generally in utter disagreement, ORL1 has been found to 
elicit hyperalgesia and is at least partially colocalized with µ-opioid receptors in synapses (Rossi, 
et al., 1997; Evans, et al., 2009). ORL1 is similar to traditional opioid receptors in that its 
hyperalgesia is insensitive to opioid receptor antagonists, and it mediates analgesia readily 
reversed by opioid antagonists.  However, ORL1’s endogenous ligand, orphanin FQ/nociceptin 
(OFQ/N) has a poor affinity for all other opioid receptors (Rossi et al., 1997; Bertorelli et al., 
1999), and importantly, the receptor itself has low affinity for classic opioids (Rossi, Leventhal, 
& Pasternak, 1996; Barlocco, Cignarella, Giardina, & Toma, 2000). 
 
There are similarities between the classic opioid receptors and ORL1, both structurally and 
functionally.  However, while ORL1 activation via nociceptin does inhibit cAMP accumulation 
(Peluso, LaForge, Matthes, Kreek, Kieffer, et al., 1998; Fawzi, Zhang, Weig, Hawes, & 
Graziano, 1997), activates K+ channels, and inhibits Ca2+ currents similar to the other opioid 
receptors (Lou, Zhang, Ma, & Pei, 1998), differences arise in in terms of effect.  For example, 
studies have found that ORL1 hyperalgesia is immediately evident after intracerebroventricular 
injection of nociceptin in mice that is insensitive to naloxone, and persists for minimally 50 
minutes post-injection, demonstrating a slightly different dose-response curve than that of 
morphine (Reinscheid, Nothacker, Bourson, Ardati, Henningsen, et al., 1995; Hara, Minami, 
Okuda-Ashitaka, Sugimoto, Sakai, et al., 1997; Meunier, Mollereau, Toll, Suaudeau, Moisand, et 
al., 2002; Suaudeau, Florin, Meuier, & Costentin, 2009).  Others have found that intrathecal 
injection of nociceptin causes paralysis in mice (Reinscheid et al., 1995).  However, some studies 
have found that intrathecal injections cause potent antinociception that is reversed by naltrexone 




(Okuda-Ashitaka, Tachibana, Houtani, Minami, Masu, et al., 1996; Hara, Minami, Okuda-
Ashitaka, Sugimoto, Sakai, et al., 1997).  Other groups have demonstrated naloxone-reversible 
analgesia following a period of rapid onset hyperalgesia after nociceptin injection, indicating 
likely mediation by an unidentified ORL1 subtype (Rossi, Leventhal, & Pasternak, 1996).  Due to 
these unreliable and often contradictory results in terms of analgesia and particularly 
hyperalgesia, ORL1 and its ligand nociceptin are unlikely mediators of opioid-induced 
hyperalgesia. 
 
Spinal µ-opioid receptors are the primary subtype found on central terminals of afferent neurons, 
suggested after autoradiographic studies following dorsal root rhizotomy.  The remaining 
subtypes reside on interneurons or second order neurons that transmit nociceptive information to 
higher order supraspinal sites (Ossipov et al., 2004).  Such findings are in support of 
pharmacological studies of opioid receptor binding in the spinal cord; intrathecal injections of µ-
receptor agonists illustrated a superior analgesic effect, with δ- and κ-receptor ligands producing 
less potent or nonexistent effects via spinal mechanisms (Leighton et al., 1988; Besse et al., 
1990).  However, other studies have illustrated an ability of agonists for all three subtypes to 
induce an analgesic effect when administered spinally, lending further credence to the notion of 
differentially distributed opioid receptor subtypes at the various levels of the spinal cord 
(Quirion, 1984).  For example, δ-opioid receptor agonists have been found to inhibit the 
transmission of pain signals from primary sensory afferents in laminae I and II to projection 
neurons in the spinothalamic tract, contributing to evidence of a greater concentration of δ-opioid 
receptors in the outer laminae of the dorsal horn relative to the deeper layers.  Morphine and 




after intrathecal administration in rat (Yaksh, Huang, & Rudy, 1977a).  Interestingly, it has been 
shown that transection of the spinal cord causes a loss in potency of systemic morphine in 
response to thermal nociceptive stimuli, while the effect of spinally administered morphine 
remains intact.  Such evidence supports the prevailing notion that opioids act directly on spinal 
sites to modulate nociceptive inputs (Advokat & Burton, 1987).  Additional support for this 
notion can be found in studies showing that the functional blockade of spinal opioid receptors 
leads to a marked reduction in the analgesic potency of opioids (Hara, et al., 1999). 
 
1c.   Opioid receptor modulation of nociception.  In addition to having a differential distribution 
in the spinal cord, each subtype has been shown to modulate a specific class of nociceptive 
perceptions.  While µ-opioid receptor agonists appear to be equally active in both thermal and 
visceral nociception, thermal and visceral nociception have been shown to be processed 
respectively by δ- and κ- opioid receptor agonists (Quirion, 1984).  All three subtypes are 
expressed primarily in afferent nociceptive C- and Aδ fibers of the dorsal root ganglia (DRG) 
cells as shown by immunohistochemistical methods (Dado, Law, Loh, & Elde, 1993; Arvidsson, 
et al., 1995).  Nociceptive signals are carried from peripheral terminals to the dorsal horn by the 
slow, unmyelinated C fibers, where they are communicated to the second-order projection 
neurons of the spinothalamic tract.  The first phase of pain, commonly associated with sensations 
of immediate, sharp painful sensations is modulated by the fast-conducting Aδ fibers, while 
duller, longer lasting pain sensations are a result of the involvement of slower conducting C 
fibers; physiological changes in these latter fibers are often the culprit in the hyperalgesia and 
allodynia experienced by post-herpetic neuralgia patients (Fields, Rowbotham, & Baron, 1998; 





Descending inhibitory projections from supraspinal sites that are activated by opioid receptors 
also regulate nociceptive signals entering the spinal cord.  In addition to spinal loci, studies have 
shown significant levels of opioid receptor mRNA in cortical, diencephalic, and brainstem 
regions (Quirion, 1984).  With regard to cranial distribution, the µ-opioid receptor is densely 
disseminated in the anterior cingulate cortex, neocortex, amygdala, hippocampus, ventral dentate 
gyrus, presubiculum, nucleus accumbens, thalamus, habenula, interpeduncular nucleus, the 
periaqueductal gray, both the superior and inferior colliculi, and the raphe nuclei, with 
particularly dense concentrations in the caudate putamen.  The δ-opioid receptor is not quite as 
diffuse; it can be found in the anterior cingulate cortex, neocortex, amygdala, olfactory tubercle, 
nucleus accumbens, the superior and inferior colliculi, the raphe nuclei, and the caudate 
putamen, and is particularly dense ventrolaterally.  Finally, κ-opioid receptors are densely 
distributed throughout the amygdala, olfactory tubercle, nucleus accumbens, caudate putamen, 
medial preoptic area, hypothalamus, median eminence, periventricular thalamus, and the 
interpeduncular nucleus, and are particularly concentrated ventromedially (Mansour, 
Khachaturian, Lewis, Akil, & Watson, 1987).  All three opioid receptor subtypes are found pre- 
and postsynaptically, and are often present within the same neuron (Ossipov et al., 2004).   
 
Descending control of pain arises from multiple supraspinal sites.  Generally, opioid receptors 
can also be found throughout the frontal cortex, hippocampus, thalamus, hypothalamus, 
periaqueductal gray (PAG) and the rostroventral medulla (RVM).  The latter two brain regions 
are most commonly associated with opioid-mediated antinociception, and share reciprocal 




2004).  Specifically, opioids activate cells in the PAG that in turn excite neurons in the RVM. 
 
It is speculated that opioid-induced antinociception is modulated, at least in part, by descending 
pathways originating from the PAG, indicated by studies using microinjection of morphine into 
this area.  It has been shown that antinociception initiated in the PAG is at least partially 
mediated by noradrenergic neurons, which are not present in the PAG (Fang & Proudfit, 1998; 
Bajic & Proudfit, 1999).  Intracerebroventricular microinjection of morphine has been shown to 
produce antinociception in rodents (Porreca et al., 1984); additionally, microinjection into the 
ventrolateral PAG has also been shown to appease the activity of projection neurons in the dorsal 
horn in response to peripheral nociceptive stimuli (Bennett & Mayer, 1979; Lewis & Gebhart, 
1977a, 1977b).  In addition to the RVM, the PAG is also heavily interconnected with the 
hypothalamus and limbic forebrain structures including the amygdala, anterior cingulate cortex, 
and medial prefrontal cortex (Heinricher, Tavares, Leith, & Lumb, 2009). 
 
While opioids activate neurons in the PAG, these projections directly interact with the RVM, 
resulting in excitation (Basbaum, Clanton, & Fields, 1978; Basbaum & Fields, 1978, 1984).  The 
RVM is also a critical region to bidirectional nociceptive modulation, as it receives inputs from 
the dorsal horn of the spinal cord and additional rostral sites, and projects diffusely to both 
superficial and deep laminae of the dorsal horn (Zhuo & Gebhart, 1997).  The RVM is the region 
of the medulla including the nucleus raphe magnus, the nucleus gigantocellularius pars alpha, 
and surrounding reticular neurons ventral to the nucleus gigantocellularius and extending 
between the caudal facial nucleus and the inferior olivary complex (Ossipov et al., 2004).  




nociceptive thresholds, as well as a weakened analgesic response to morphine (Proudfit, 1980).  
Thus, the PAG-RVM system plays a large role in inhibitory control and serves to suppress 
nociceptive inputs (Morgan, Whittier, Hegarty, & Aicher, 2008). 
 
Analysis of molecular circuitry of the RVM through electrophysiological studies has revealed 
populations of specialized neurons termed “on”, “off”, and “neutral” cells.  These cells are 
considered to be the neural basis for the bidirectional control that the RVM has in nociception 
(Fields & Heinricher, 1985; Fields, Heinricher, & Mason, 1991; Heinricher & Morgan, 1992; 
Neubert, Kincaid, & Heinricher, 2004; Ossipov et al., 2004; Heinricher et al., 2009).  The off-
cells continuously discharge in a tonic manner in response to the initiation of nociceptive input, 
and pause immediately before an animal’s behavioral response to a noxious stimulus.  At this 
point, on-cell firing accelerates.  Therefore, the on-cells are associated with the modulation of 
behavioral reflexes involved in pain (Heinricher, Barbaro, & Fields, 1989; Ossipov et al., 2004).  
In other words, behavioral responses to noxious thermal stimuli such as the tail flick or paw 
withdrawal are marked by a shift in the activity of RVM-cell populations, such that as the on-
cells are activated, the off-cells become silent (Heinricher et al., 1989).  It is now generally 
believed that off-cells function to produce a net inhibitory effect on nociception.  Additionally, 
Boyer, Morgan, and Craft (1998) found that when morphine was microinjected into the RVM, 
male rats demonstrated superior antinociception when compared to female rats (and they 
hypothesized this sex difference to be at least partly regulated by the RVM itself).  However, it 
has more recently been proposed that in addition to inhibiting pain, this system may also 
facilitate nociception with on-cells likely having a large role in this process as the mediators of 




instance, neurotensin is a tridecapeptide known to elicit hyperalgesia at low doses, whereas 
microinjection into the RVM has been shown to induce analgesia at high doses (Buhler, Proudfit, 
& Gebhart, 2008).  In rats, neurotensin has been shown to selectively activate on-cells when low 
doses are given, resulting in enhanced nociception, or hyperalgesia.  Furthermore, higher doses 
of neurotensin additionally activate off-cells and elicit antinociception (Zhou & Gebhart, 1997; 
Urban & Gebhart, 1999). 
 
Additional studies using microinjections of capsaicin into the PAG induced hyperalgesic states 
as measured by the tail flick test, followed later by an analgesic state, that were correlated with 
bursts of RVM on-cell and off-cell activity, respectively (McGaraughty et al., 2003).  It is 
therefore believed that on-cells play a significant role in the facilitation of nociception, enhanced 
sensitivity to noxious stimuli, and reduced sensitivity to analgesic drugs, while off-cells mediate 
descending antinociceptive inputs from the RVM (McGaraughty et al., 2003; Neubert et al., 
2004).  Neutral-cells were originally characterized by the absence of a reaction to deleterious 
stimuli (Ossipov et al., 2004), as they show no response to noxious stimuli; however, it is now 
believed that they may be recruited when necessary to assist on- or off-cells, as studies have 
shown such phenotypic conversions during chronic pain states.  Studies have also shown an 
increase in both on- and off-cell populations and a corresponding decrease in neutral-cells 24 
hours after inflammation when compared to naïve animals (Miki et al., 2002). 
 
While the PAG predominately expresses the µ-opioid receptor subtype with little to no 
manifestation of the others, the RVM has been shown to contain all three subtypes, although still 




the locus coeruleus has also been shown to have a role in the modulation of nociceptive inputs 
and also expresses opioid receptors.  Finally, the serotingergic nucleus raphe magnus may 
function to relay nociceptive information from the PAG to descending pathways throughout the 
spinal cord.  Overall, it appears that opioids exert their effects via synergistic interactions 
between activity at spinal and supraspinal loci (Ossipov, 2004).  What remains nebulous is the 
interaction between these receptors, their corresponding pathways, their actions in various brain 
areas, and if or how all of these variables contribute to hyperalgesia following opioid treatment. 
 
2. Prevalence of Opioid-Induced Hyperalgesia 
2a. Human studies     Although a majority of research on opioid-induced hyperalgesia (OIH) is 
comprised of animal studies, the obvious application of such research is the use of opioids in 
clinical settings involving treatment of pain, where this phenomenon inserts a complication.  The 
success of pain treatment in humans is hindered by the appearance of hyperalgesia, where opioid 
titration and rotation become a potentially dangerous guessing game.  Further complicating the 
issue is the inability to reliably predict or elicit opioid-induced hyperalgesia in clinical settings.  
That is, there is little literature to consistently support the existence of OIH under reliable 
circumstances (Lee et al., 2011).  As opioids have become a cornerstone for treatment of pain 
related to health issues such as cancer and surgical procedures, understanding the mechanisms 
underlying OIH is imperative in order for clinicians to effectively address patient needs.  As 
such, there have been studies sporadically conducted in the human population using 
observational case studies, as well as cross-sectional methodology.  A majority of these studies 
focus on a few particular cohorts; for example, patients suffering from chronic illnesses such as 




addicts (both former and current), and healthy volunteers undergoing human experimental pain 
testing. 
 
In one series of four case studies of patients with cancer (Sjøgren, Jensen, & Jensen, 1994), 
morphine-induced hyperalgesia disappeared after the cessation of morphine administration, or 
also when treatment with various other opioids was substituted for morphine.  For instance, a 
young girl undergoing intravenous (i.v.) morphine infusion developed both hyperalgesia and 
myoclonus, which was obfuscated when the i.v. morphine was discontinued.  Following the 
cessation of morphine, she was maintained on occasional doses of oral methadone instead and 
thus relatively free of hyperalgesic symptoms.  In a second case, hyperalgesia evoked by a small 
dose of sustained-released morphine was obfuscated after the patient was alternatively given an 
oral regimen of ketobemidone.  A third case describes a patient in which injections of high dose 
intramuscular (i.m.) morphine was given, where hyperalgesia was eliminated following the 
substitution of subcutaneous (s.c.)  sufentanil.  Finally, the case of a boy is described in which 
hyperalgesia was evident following a regimen of high doses of both oral and i.m. morphine.  In 
his case, hyperalgesia subsided after morphine treatment was discontinued (Sjøgren, Jensen, & 
Jensen, 1994).  In another case study (Mercadante & Acuri, 2005), a 48-year-old man with 
diagnosed chest sarcoma complained of severe pain in various regions, and was subsequently 
placed on a regimen of fentanyl patches with additional adjuvant doses of oral morphine in an 
unsuccessful attempt to treat the aforementioned pain.  Additionally, the patient developed 
myoclonus as a result of opioid treatment.  While reducing the fentanyl dose, an adjuvant 
prescription of methadone was given that reduced the patient’s pain completely within eight 





In a study of ninety patients who had undergone laparoendoscopic urologic surgery, patients 
received high-dose remifentanil for the treatment of postoperative pain and subsequently 
developed hyperalgesia.  However, it was found that a single oral dose of pregabalin, a 
gabapentinoid compound, effectively attenuated these symptoms (Lee, Lee, & Kim, 2013).  In a 
controlled using a double-blind study on the use of perioperative analgesics performed by Chia, 
Liu, Wang, Kuo, and Ho (1999), the investigators found that post-operative consumption of 
fentanyl was of greater magnitude when intraoperative doses of the drug were higher, as 
compared to a low dose cohort.  Specifically, 60 female patients undergoing abdominal 
hysterectomy were randomly assigned to either a group to receive 1µg/kg of fentanyl prior to 
surgery (low dose group), or a group receiving 15µg/kg prior to surgery and maintained on 
100µg/hr during surgery (high dose group).  Measured at both four and eight hours 
postoperatively, patients in the high dose group reported higher pain intensity and subsequently 
required more postoperative fentanyl to relieve their pain states.  While the authors attribute this 
difference in pain intensity to the development of tolerance (Chia et al., 1999), it could very well 
be a clinical manifestation of hyperalgesia that is independent of the development of tolerance 
(Juni, Klein, & Kest, 2006), as fentanyl has been found to elicit this phenomenon in both acute 
and chronic paradigms in mice (Waxman et al., 2009). 
 
Presumably attributable to its NMDAR-antagonistic properties, although weak, some 
practitioners report the successful use of adjuvant methadone to control opioid-induced 
hyperalgesia.  This was the case in several of the above-mentioned case studies, and additionally 




malignant pain and was unsuccessfully treated with numerous other opioids.  Nonetheless, there 
remains an abundance of unresolved conflict in the literature regarding clinical manifestations of 
OIH. 
 
Doverty et al. (2001a) note the inconsistencies in the literature and attributed them to the array of 
pain modalities and tests used to assess opioid-induced hyperalgesia.  In an effort to resolve the 
conflicting literature, Doverty et al. (2001a) conducted a study using 16 patients enrolled in the 
South Australian Public Methadone Maintenance Program.  In their study, the investigators 
counterbalanced two pain induction methods: electrical stimulation and the cold pressor test.  In 
order to induce pain via electrical stimulation, a cutaneous electrode was attached to one ear lobe 
and pulses lasting for 14ms were delivered.  Beginning at 0 volts, electricity increased every 1.4 
seconds by 2 volts, and participants verbally indicated the first perception of the stimulus as 
painful, and resultant increases in pain up until they could no longer tolerate it.  The 
methodology for the cold pressor test was adapted from the procedures of Eckhardt et al. (1998, 
as cited in Doverty et al., 2001a), where patients essentially held their arm in ice water until they, 
again, could no longer tolerate the pain.  Both measures were reliant on participant’s subjective 
reports of pain. Additionally, they accounted for fluctuations in plasma concentrations of 
methadone over time using liquid chromatographic methods.  Doverty et al. (2001a) found that 
on tests of electrical stimulation, 30 minutes prior to their daily scheduled dose of methadone (0 
hours), patients maintained on methadone had a lower tolerance for pain (i.e. they reported 
intolerance of the electrical stimulation at a significantly lower voltage) when compared to their 
control counterparts.  However, three hours after the initial test (and thus 2.5 hours after their 




methadone maintenance patients reported the stimulus as painful at a lower voltage), as well as 
in the tolerance of said pain (i.e. methadone maintenance patients again reported intolerance of 
the electrical stimulation at a significantly lower voltage) when patients maintained on 
methadone were compared to the control patients not receiving methadone.  Interestingly, on the 
cold pressor test, patients maintained on methadone reported both a decrease in detection and 
tolerance of pain at both 0 hours and three hours later when compared to their control 
counterparts, thus exhibiting significant hyperalgesia as a result of methadone maintenance.  
Additionally, Doverty et al. (2001a) found that at trough plasma concentrations of methadone, 
patients had similar threshold detection values as controls, and were less pain-sensitive than 
controls at their peak methadone plasma concentration.  Finally, in a follow-up study, Doverty et 
al. (2001b) also found that methadone maintenance patients are cross-tolerant to the 
antinociceptive properties of morphine, such that attempting to treat acute pain in these patients 
using conventional doses of morphine is unsuccessful. 
 
Another popular cohort of study in clinical applications of opioid-induced hyperalgesia includes 
healthy, non-opioid dependent volunteers undergoing acute opioid treatment.  Compton, 
Athanasos, & Elashoff (2003) conducted a preliminary study using the cold pressor test to assess 
hyperalgesia after administration of three different opioid protocols (i.m. morphine, i.v. 
morphine, or i.v. hydromorphone) and subsequent naloxone-precipitated withdrawal.  When 
compared to their placebo condition, the participants in this study had markedly and reproducibly 
reduced thresholds and tolerance to the cold-pressor test, sometimes as much as 70% of their 
initial baseline.  However, the fact that this study employed a within-subjects design, although 




Participants’ responses could have differed based solely on the fact that they had previously 
received opioids in this very study, such that they are not truly opioid-naïve after participating in 
the first condition.  Additionally, this study only used men and thus leaves an important area of 
investigation unfounded: gender differences in clinical applications of opioid-induced 
hyperalgesia.  Finally, preclinical research has shown that hyperalgesia is not merely a side effect 
of opioid withdrawal, and can readily occur as its own independent phenomenon (Juni, Klein, & 
Kest, 2006).  In short, reliable, non-confounded clinical applications of opioid-induced 
hyperalgesia have remained lacking. 
 
In an attempt to address the limitations consistently present in the literature, including cross-
sectional designs, failure to distinguish between tolerance and hyperalgesia, and the use of 
patients who have previously received opioids, Chu and colleagues conducted an observational 
study using opioid-naïve pain patients beginning chronic oral opioid therapy for persistent lower 
back pain (Chu, Clark, & Angst, 2006).  Both analgesic tolerance and hyperalgesia using cold 
pressor and experimental heat pain paradigms were assessed after one month of oral morphine 
treatment.  Patients demonstrated significant hyperalgesia and analgesic tolerance on the cold 
pressor test but not heat pain models, partially supporting previous findings in populations who 
have received chronic opioid treatment as well (Chu, Clark, & Angst, 2006; Doverty et al., 
2001a; Doverty et al., 2001b).  Such evidence supports the notion that hyperalgesia is specific to 
certain pharmacologic agents as well as pain modalities; such that one’s modality-specific 
hyperalgesic response after one opioid may differ vastly when tested using another nociceptive 





2b. Animal studies      Over the past few decades, there has been an increasingly growing interest 
in opioid-induced hyperalgesia and its underlying mechanisms.  As seen above, research 
addressing clinical applications of this phenomenon is relatively limited.  However, there is an 
abundance of available literature on this topic using animal models.  In 2006, Angst and Clark 
conducted a comprehensive review from over 100 publications on OIH in animals, which 
demonstrated increased pain sensitivity induced by opioid exposure on measures of thermal, 
chemical, mechanical, and electrical pain. Despite wide variations in methodology and animal 
species under study, the authors were surprised by the lack of agreement on a pathway mediating 
OIH, and instead found evidence for numerous pathways as contributors to pain processing. 
Similar to findings from human studies, manipulations that produce profound OIH on one pain 
assay may show no hyperalgesic liabilities on other assays, suggesting that OIH is drug and 
modality specific, and likely influenced by varying genetic backgrounds in animals as well 
(Angst & Clark, 2006; Mogil et al., 1999a; Mogil et al., 1999b). 
 
In general, animal models of opioid-induced hyperalgesia follow two basic paradigms based on 
the duration of opioid exposure.  Acute paradigms typically involve the systemic administration 
of a single opioid dose and the observation of resulting changes in behavioral responses.  In such 
paradigms, a dose-dependent, biphasic role for morphine and other µ receptor agonists has been 
found, whereby animals demonstrate intense antinociceptive effects followed by periods of 
enhanced pain sensitivity typically lasting three to four hours (Ding & Bayer, 1993; Larcher, 
Laulin, Celerier, Le, & Simonnet, 1998; Laulin, Larcher, Celerier, Le, & Simonnet, 1998; 
Celerier, Laulin, Larcher, Le, & Simonnet, 1999; Crain & Shen, 2001; Borgland, 2001; Xu, 





The majority of studies investigating OIH use chronic administration paradigms, where animals 
are administered opioids for a range of three to fourteen days, using a variety of routes including 
multiple daily injections, subcutaneous pellet or osmotic pump implantation, or intrathecal 
catheters. Here too, biphasic responses are consistently observed, with said opioids eliciting 
antinociception generally lasting one to three days.  Following this analgesic period, there is a 
gradual hyperalgesic onset (Laulin, Celerier, Larcher, Le, & Simonnet, 1999; Li, Angst, & Clark, 
2001a; Li, Angst, & Clark, 2001b; Gardell et al., 2002; Bie & Pan, 2003; Ossipov, Lai, 
Vanderah, & Porreca, 2003; Kest, Palmese, Juni, Chesler, & Mogil, 2004; Coutaux, Adam, 
Willer, & Le, 2005; Juni et al., 2006).  Furthermore, the finding of hyperalgesia in animal studies 
using uninterrupted opioid delivery paradigms (Celerier et al., 2000; Celerier, Laulin, Corcuff, 
Le, & Simonnet, 2001; Kest et al., 2002; Simonnet & Rivat, 2003; Ossipov, Lai, King, 
Vanderah, & Porreca, 2005; Vanderah et al., 2001a; Juni et al., 2006), supports the idea that 
nociception is not simply a consequence of opioid withdrawal, as could be the case in studies 
using multiple injection paradigms, but rather a direct consequence of opioid treatment.  Thus, 
there is a growing body of evidence elucidating a dual-role for morphine as well as other opioids, 
whereby these agents produce coinciding activation of two paradoxical mechanisms; the first 
being an intense but short-lasting pain inhibitory phase (analgesia), and a weaker but longer-
lasting pronociceptive period (hyperalgesia).  Although concomitantly present during the 
analgesic phase, the hyperalgesic effect is often not observed immediately because it is allegedly 
masked by this simultaneous analgesia, and thus can only be evident after analgesia subsides.  
However, this initial hyperalgesia can be unmasked, as is the case in studies using either sub-




CXBK mice that show reduced analgesic responses due to their µ-opioid receptor deficiency (Li 
et al., 2001a).  Altogether, this suggests that hyperalgesia may be a direct consequence of opioid 
exposure that is independent of prior analgesic processes. 
 
3. Mechanisms of Opioid-Induced Hyperalgesia 
3a. Opioid-Related Mechanisms     Pioneering research by Collier and colleagues (1974, 1981) 
uncovered the notion that hyperalgesia may not be a phenomenon elicited solely by the 
administration of exogenous opioids, but that this process may be modulated by the endogenous 
opioid system, particularly the kappa opioid receptor.  Collier et al. (1974) first identified a 
“quasi-morphine withdrawal syndrome (QMWS)” and defined it as behaviors characteristic of an 
opioid-dependent animal experiencing actual morphine withdrawal, but present in an opioid-
naïve animal given non-opioid drugs.  Additionally, during a state of QMWS, the effects of 
opioids and their antagonists should be analogous to those undergoing true opioid withdrawal.  
For instance, Collier et al. (1981) found that QMWS is extraordinarily similar to naloxone-
precipitated withdrawal seen in animals dependent on morphine.  Such drugs that, when injected 
into naïve rodents, elicit QMWS (including hyperalgesia) are 3-isobutyl-1-methylxanthine 
(IBMX), theophylline, and caffeine.  Collier et al. (1984) proposed that these drugs act by 
inhibiting cAMP phosphodiesterase (cAMP-PDE), which in turn raises the amount of cAMP 
available in the brain.  A parallel of the aforementioned drugs to true opioids lies in the fact that 
opioid dependence is characterized by an increase in cAMP, that which is originally caused by 
an opioid’s tendency to inhibit adenylyl cyclase.  Essentially, these non-opiate drugs elicit 
hyperalgesia akin to that seen after morphine treatment by causing the release of endogenous 





Crain and Shen (2008) extended Collier et al.’s (1974, 1981) research by illustrating that a more 
specific cAMP-PDE inhibitor, rolipram, rapidly evokes thermal hyperalgesia in mice, mediated 
by excitatory opioid receptor signaling.  However, extending their own research beyond their 
original findings with exogenous opioids (Crain and Shen, 1994; Shen and Crain, 1998; Crain 
and Shen, 2000), Crain and Shen (2008) found that this effect is blocked by cotreatment of low-
dose naltrexone, and in fact a state of endogenous, bimodally acting (excitatory/inhibitory) 
opioid-mediated analgesia is exposed.  Additionally, the same analgesic effect is found when 
naltrexone is replaced with the kappa-opioid receptor antagonist nor-binaltorphimine (nor-BNI) 
or the mu-opioid receptor antagonist β-funaltrexamine (β-FNA).  The aforementioned research 
provides a base by which the endogenous opioid system could potentially be used in the 
management of pain when specific cAMP-PDE inhibitors and low-dose naltrexone, nor-BNI, or 
β-FNA are combined.  However, this research was performed using paradigms formulated within 
the mouse spinal cord, and thus the degree of applicability of these effects to supraspinal centers 
as well as general extrapolation is unknown. 
 
In a series of electrophysiological studies, Crain and Shen (1994) demonstrated that while 
extremely low doses of many mu-, kappa-, and delta-opioid receptor agonists can elicit 
excitatory effects on their respective receptors (resulting in hyperalgesia), higher doses evoke 
inhibition of these receptors (resulting in analgesia), indicating a need for higher doses of opioids 
in the treatment of pain (Shen and Crain, 1998).  More recent studies have shown that these low, 
subanalgesic doses of morphine may actually be sufficient for the treatment of chronic pain, but 




found that although extremely low doses of morphine (ca. 0.1 mg/kg) elicited hyperalgesia in 
mice, this effect was blocked by concomitant treatment of equally low doses of naltrexone (ca. 
1–100 pg/kg).  Additionally, this accompanying treatment unmasked potent analgesia, and thus 
can be used to make lower doses of opioids effective, such that patients did not require quite as 
much drug to alleviate their chronic pain states.  In turn, this can alleviate adverse affects (Crain 
& Shen, 2000). Shen and Crain (1998) reported clinical evidence from 60 post-hysterectomy 
patients with the ability to self-administer morphine, such that patients receiving morphine in 
conjunction with low doses of the opioid antagonist naloxone required less morphine to alleviate 
their post-operative pain when compared to patients only receiving morphine, indicative of the 
development of tolerance in the latter group.  This evidence provides a possible solution to the 
manifestation of hyperalgesia in clinical settings, where there exists a delicate balance between 
the prescription of opioids in attempt to alleviate pain and hyperalgesia, and the consequent 
increase in this phenomenon due to the protocol currently used to avoid it (titration of the drug). 
 
Shen and Crain (1998) found that GM1 ganglioside, a member of the cAMP-PKA-dependent 
glycolipid family shown to regulate the binding of growth factors and to manipulate second-
messenger systems, has a role unique to the opioid system.  Specifically, alterations in the 
concentration of GM1 ganglioside are likely responsible for the conversion of opioid receptors 
from inhibitory (Gi/Go second messenger-coupled) to excitatory (Gs-coupled), and vis-à-vis, such 
that intraperitoneal (i.p.) injections of this glycolipid rapidly weaken the analgesic effects of 
morphine.  Additionally, where naloxone is known to induce hyperalgesia as a result of physical 
dependence in mice treated with chronic morphine, a similar state is evoked by injection of a low 




receptor antagonist nor-binaltorphimine blocks this naloxone-evoked hyperalgesia.  In fact, 
treatment with naltrexone or nor-binaltorphimine in GM1 pre-treated mice produces potent 
analgesia, likely by some mechanism involving the release of endogenous opioid agonists via 
inhibitory kappa opioid receptor signaling.  Such evidence suggests a possible role for this 
glycolipid in morphine-induced hyperalgesia (Crain & Shen, 2007).  In accordance, the binding 
of GM1 by extremely low doses of the non-toxic B-subunit of cholera toxin (CTX-B) blocked 
the excitatory but not inhibitory effects of morphine, such that CTX-B blocks morphine-induced 
hyperalgesia (Shen and Crain, 2001). Such results were similar to those obtained that showed a 
reduction in the manifestation of morphine hyperalgesia and accompanying increases in 
morphine analgesia after concomitant treatment of low-dose naltrexone. Thus, the plasticity of 
GM1 ganglioside may be the cellular mechanism so highly sought after, by which opioids can 
produce both analgesic/inhibitory effects, as well as hyperalgesic/excitatory effects on opioid 
receptors. 
 
3b.  Cellular sensitization. Studies indicate that prolonged opioid treatment not only results in 
a loss of opioid analgesic efficacy, but also leads to activation of a pronociceptive system that 
results in a reduction of nociceptive thresholds, indicative of both negative system adaptation 
(desensitization) and positive system adaptation (sensitization), respectively (Mao, 2002). 
Whereas desensitization refers to the gradual weakening of a response to a repeated stimulus, or 
a reduction in neuronal signaling after repeated stimulation (Freedman & Lefkowitz, 1996), 
central sensitization refers to increased synaptic transmission/efficacy in somatosensory neurons 
of the dorsal horn as a result of peripheral noxious stimuli (Ji, Kohno, Moore, & Woolf, 2003).  




primary afferent neurons, and thereby manifests as amplification in nociceptive responses.  
Additionally, this phenomenon may also result in enhanced production, release, and spread of 
excitatory amino acid neurotransmission and the suppressed reuptake of neurotransmitters, 
and/or from neuroplastic changes of various receptor systems in the peripheral and central 
nervous system that lead to sensitization of pain pathways (Vanderah et al., 2001; Li & Clark, 
2002; Ji, Kohno, Moore, & Woolf, 2003). 
 
An upregulation of G-protein coupled neurokinin-1 receptors (NK-1) has been implicated in 
opioid-induced hyperalgesia.  Lamina I cells of the dorsal horn that express the NK-1 receptor 
have been shown to project to supraspinal areas that facilitate pain processing (Nichols et al., 
1999).  Substance P, an excitatory neurotransmitter synthesized by primary afferent nociceptors 
(McCarthy & Lawson, 1989), is the endogenous ligand for the NK-1 receptor.  It is released in 
the spinal cord dorsal horn after nociceptive stimulation (Duggan, Morton, Zhao, & Hendry, 
1987), and has been shown to have a role in central sensitization and hyperalgesia associated 
with inflammatory pain (King et al., 2005).  In fact, it has been reported that in circumstances of 
pathological pain, there is increased substance P expression in primary afferents and increased 
release of substance P upon noxious stimulation, causing internalization of NK-1 receptors in 
both superficial regions and deep laminae of the spinal cord.  Although this specific scenario is 
the neuronal substrate of inflammatory pain, this mechanism has been hypothesized to also play 
a potential role in neuronal plasticity associated with opioid-induced hyperalgesia (Takeda, 
Chou, Takeda, Sachais, & Krause, 1991).  Studies have shown that substance P in mice either 
intermittently treated or chronically exposed to morphine evoked hyperalgesia on chemical, 




c-Fos immunoreactivity in dorsal horn nuclei after morphine administration, presumably a result 
of substance P activity in these areas and indicative of neuronal sensitization.  This is supported 
by studies indicating that both systemic and intrathecal morphine treatment elicits substance P 
activity, increases spinal NK-1 receptor expression, and results in opioid-induced hyperalgesia, 
suggesting a particular role for opioid receptors in the spinal cord (Vanderah et al., 2001; Li & 
Clark, 2002; King et al., 2005). 
 
Descending facilitation of nociception from the RVM has been found to increase spinal levels of 
the endogenous opioid peptide dynorphin (Gardell et al., 2002; Wang et al., 2001; Laughlin et 
al., 1997).  Although originally believed to possess antinociceptive properties, dynorphin has 
more recently been shown to be a paradoxical kappa-opioid receptor agonist that modulates 
synaptic transmission via non-opioid receptor mechanisms (Laughlin et al., 1997).  That is, 
dynorphin potentiates naloxone-insensitive pronociception by increasing neuronal receptive field 
size and sensitizing NMDA receptors, thus increasing the release and binding of excitatory 
neurotransmitters (i.e. glutamate) and subsequent release of intracellular calcium (Laughlin et al., 
1997; Lai, Ossipov, Vanderah, Malan, & Porreca, 2001).  In fact, a single intrathecal injection of 
low dose dynorphin produces heightened sensitivity to mechanical von Frey filament stimulation 
for up to 70 days in mice.  Additionally, acute intrathecally administered dynorphin induces 
long-lasting tactile, cold, and mechanical allodynia and mechanical hyperalgesia that is blocked 
by NMDA receptor antagonists MK-801 and LY235959, and is unaffected by opioid receptor 
antagonism.  MK-801 administered following dynorphin transiently blocks allodynia, indicating 
that dynorphin-induced allodynia may not only be produced but also maintained by NMDA 




induced hyperalgesia (Laughlin et al., 1997; Vanderah et al., 1996; Vanderah et al., 2000).  
These paradigms suggest a role for spinal endogenous opioids in the descending, facilitative 
control of opioid-induced hyperalgesia. 
 
3c.   Morphine metabolites. A major area of ongoing investigation into the substrates 
underlying morphine-induced hyperalgesia is that of morphine metabolites.  Once administered 
to humans, morphine is transformed primarily in the liver by UDP-glucuronosyltransferase, and 
to a lesser extent in the brain and kidneys into two primary metabolites, morphine-3β-
glucuronide (M3G) and morphine-6β-glucuronide (M6G) (Christup, 2008; Vaughan & Connor, 
2003).  By way of the UGT2B7 isoenzyme, morphine is broken down in the liver into ninety 
percent M3G, and ten percent M6G.  Recently, it has been hypothesized from in vitro studies 
that the 9:1 ratio of M3G to M6G is due to the additional involvement of the UGT1A1 
isoenzyme in the formation of M3G; however, in vivo studies do not support anything other than 
a role for UGT2B7 in the metabolism of morphine (De Gregori et al., 2012).  In mice, a variant 
UGT isoform is involved in glucuronidation, allowing only for the formation of M3G and no 
M6G (Zelcer et al., 2005).  Thus, M6G receives little attention with regard to a role in morphine-
induced hyperalgesia, as mice to not produce this metabolite but nonetheless exhibit 
hyperalgesia. 
 
Membrane transport systems limit morphine accumulation in the brain by way of limiting 
accretion of the morphine glucuronides after morphine is biotransformed.  Studies indicate that 
multidrug resistant protein 3 (Mrp3) is the major transporter of the morphine glucuronides from 




via an unknown mechanism and are eventually excreted primarily through the urinary tract.  In 
the absence of Mrp3 in mice, M3G is transported from the hepatocytes into bile, from which it is 
excreted through biliary routes.  Two interesting observations are that absence of Mrp3 does not 
affect morphine-induced analgesia, and that analgesia is still present in mice who lack the ability 
to form the extremely potent analgesic-inducing morphine metabolite, M6G.  With that said, lack 
of Mrp3 is not ideal, as transport through bile and excretion via intestinal routes allows for 
deglucuronidation, reabsorption, and intestinal toxicity (Zelcer et al., 2005). 
 
M6G has been found to have an affinity at µ-opioid receptors that is comparable to morphine, 
and is commonly associated with superior production of longer lasting analgesic properties 
without causing many of the troublesome side effects that result from morphine treatment 
(Christup, 1997; Rossi, et al., 1997; Dahan, van Dorp, Smith, & Yassen, 2007; De Gregori, et al., 
2012).  This idea came from a series of receptor binding studies in which it became apparent that 
morphine elicits its analgesic effects via action at µ1 receptors, and that many of its side effects 
(such as respiratory depression and gastrointestinal disturbances) are mediated via action at µ2 
receptors.  M6G has little affinity for any receptor other than µ1 (Chen, Irvine, Somogyi, & 
Bochner, 1991; Pasternak, Bodnar, Clark, & Inturrisi, 1987).  Thus, M6G is likely a significant 
contributor to the analgesic effects of morphine via that receptor subtype (Francés, Gout, 
Campstron, Panconi, & Cros, 1990).  In fact, when administered systemically (subcutaneous 
injection) or centrally (via intrathecal or intracerebroventricular routes), M6G has been found to 
have an increased effect duration of anywhere from a 1.6- to 4-fold or 13- to 800-fold analgesic 
potency, respectively, when compared to morphine (Christup, 1997).  In addition, M6G has been 




ability to cross the blood brain barrier (BBB) with relative ease (De Gregori et al., 2012).  With 
that said, M6G was quickly becoming the choice analgesic over morphine in clinical settings for 
the treatment of pain.  However, M6G does cross the BBB, it does so slower than morphine, thus 
resulting in a significantly slower onset of analgesic effect (Christup, 1997).  In addition, more 
recent evidence has shown that both acute and continuous administration of M6G also results in 
a hyperalgesic state independent of opioid receptors, similar to that of morphine, reversed by an 
acute injection of the NMDA receptor antagonist MK-801 (van Dorp et al., 2009).  Because of 
such recent findings, M6G is less and less often considered the golden alternative to morphine in 
the treatment of pain. 
 
Morphine-3β-glucuronide is the primary result of morphine biotransformation in humans and the 
only morphine metabolite produced in rodents.  It is speculated to have a significant role in 
morphine-induced hyperalgesia and the development of tolerance.  Importantly, M3G has no 
appreciable affinity at any opioid receptor subtype (Labella et al., 1979) and therefore no 
analgesic potency, and the wide-spectrum opioid antagonist naloxone does not block its 
pronociceptive effects (Juni et al., 2006).  In addition, M3G has been reported to antagonize the 
antinociceptive effects of morphine and M6G, and is postulated to contribute to the respiratory 
depression seen after morphine treatment (Christup, 1997).  Not fully understood is the 
relationship between morphine-induced hyperalgesia and M3G, if any.  Juni, Klein, & Kest 
(2006) report hyperalgesic cross-adaptation between morphine and M3G, after seven days of low 
dose morphine infusion followed by an acute injection of M3G.  However, Swartjes et al. (2012) 
report a negative correlation between acute morphine-induced hyperalgesia and plasma levels of 




Additionally, there is no evidence to support M3G directly interacting with the MC1R system, 
and thus M3G is an unlikely candidate in the mediation of morphine hyperalgesia.  Yet, there 
does appear to be a functional relationship between the other major morphine metabolite, M6G, 
and MC1Rs, as e/e mice and humans lacking functional MC1Rs both exhibit significantly more 
powerful analgesia after M6G administration (Mogil et al., 2005). 
 
Injecting M3G in rodents via the intracerebroventricular (i.c.v.) (Labella et al., 1979), intrathecal 
(i.t.) (Woolf, 1981), or systemic/subcutaneous (s.c.) (Juni et al., 2006) route has been found to 
enhance nociception.  Interestingly, i.t. injections of M3G reportedly induced hyperesthesia and 
allodynia (Yaksh, Harty, & Onofrio, 1986), while i.c.v. injections induced a variety of other 
excitatory behaviors such as excessive grooming, “wet dog” shakes (Bartlett, Cramond, & Smith, 
1994), lethargy, and seizure-like behavior (Arout, Caldwell, McCloskey, & Kest, unpublished 
observations), suggesting the involvement of a variety of non-opioid receptor systems within the 
central nervous system.  Furthermore, both naloxone (NLX) and naltrexone (NTX) exacerbate 
these excitatory behaviors, providing further evidence for non-opioid receptor involvement in the 
pharmacodynamics of M3G (Christup, 1997). 
 
Notably, it appears that even after administration of the general opioid antagonist naltrexone, 
M3G is still significantly more active in the PAG when compared to morphine also preceded by 
NTX, via unknown mechanisms (Arout, Caldwell, McCloskey, & Kest, unpublished 
observations).  Interestingly, the PAG is rich in µ-opioid receptors (as well as other receptors 
systems implicated in morphine-induced hyperalgesia) and is known for its role in pain 




neuroanatomical area (Mansour et al., 1987).  Several studies have indicated a role for the PAG 
in hyperalgesia, such that a significant decrease in paw withdrawal latency was observed in rats 
receiving microinjections of prostaglandin E2 (an autocrine/paracrine hormone implicated in 
inflammatory pain; Portanova, Zhang, Anderson, Hauser, Masferrer, et al., 1996) directly into 
the ventrolateral PAG, hypothesized to be mediated via communication with the RVM 
(Heinricher et al., 2004).  In rats with chronic allodynia, Pertovaara et al. (1996) supported this 
finding with a report that this hyperalgesic state was in fact mediated by the RVM and PAG, and 
attenuated by lidocaine treatment.  In addition, no role for opiate receptors was found in the latter 
study (Pertovaara et al., 1996).  Consequently, M3G accumulation subsequent to morphine 
injection could conceivably cause hyperalgesia. 
 
A role for M3G in morphine hyperalgesia has been proposed in humans and rats (Woolf, 1981).  
However, the activity of M3G is poorly characterized.  There is a potential role for the GABAA 
receptor complex in the mediation of M3G; Bartlett et al. (1994) have shown that midazolam (a 
GABAA receptor agonist) attenuates the excitatory behaviors elicited by the morphine 
metabolite, although M3G has not been shown to have an affinity for this receptor complex.  
M3G is also thought to activate (though not bind) NMDA receptors, a finding consistent with the 
ability of MK-801 to reverse morphine hyperalgesia, as well as findings of the functional 
antagonism of the excitatory behavioral effects of M3G by the NMDA receptor antagonist 
LY274614 (Bartlett et al., 1994).  It is therefore feasible that this metabolite is working indirectly 
with the NMDA receptor system; however, while the NMDA receptor antagonist MK-801 
reverses morphine-induced hyperalgesia (Juni et al., 2006; Juni et al., 2008; Waxman et al., 




mechanisms underlying these hyperalgesic states (Arout, Caldwell, McCloskey, & Kest, 
unpublished observations). Therefore, it is likely that M3G elicits hyperalgesia via another 
unknown receptor system. 
 
Both morphine and M3G have been reported to have significant activity at the toll-like receptor 4 
(TLR4), whereas its analgesia-inducing morphine metabolite counterpart M6G showed no such 
activity (Hutchinson et al., 2010; Lewis et al., 2010).  This receptor system is therefore indicated 
in the manifestation of neuroexcitatory effects of morphine and M3G (Due, Piekarz, Wilson, 
Fledman, Ripsch, et al., 2012).  However, while NTX increases morphine glucuronidation and 
thus results in increased concentrations of M3G (Antonilli, Petecchia, Caprioli, Badiani, & 
Nencini, 2005), it has also been found to be a TLR4 antagonist (Li, 2012), so any paradigm 
employing NTX pretreatment should conceivably narrow the possibility of M3G (or morphine) 
working directly via TLR4 to mediate hyperalgesia.  Indeed, recent research (Lewis et al., 2010) 
indicates a role for M3G working indirectly via this receptor system to modulate a microglial-
originated state of TLR4 regulated hyperalgesia.  That is, it is possible that M3G is producing 
hyperalgesia that is initiated via a glial cell mechanism, as both astrocytes and microglia have 
been found to express all three subtypes of opioid receptors and play a role in the development of 
opioid-induced side effects.  As such, these glial cells in part cause the release of numerous 
neuroexcitatory transmitters, proinflammatory cytokines, and neuromodulators, which in turn 
produce increased excitability via direct and indirect connections to AMPA and NMDA receptor 
pathways, and downregulation of GABA receptors (Li, 2012).  Such evidence supports the 
notion that opioid-induced hyperalgesia is a response elicited by the body to counteract analgesia 




immune response in itself (Watkins, Hutchinson, Rice, & Maier, 2009).  However, whether this 
immune response-elicited hyperalgesia is the same to that seen after morphine treatment is 
unknown.  Seeing as M3G has no affinity for opioid receptors and has demonstrated activity at 
TLR4, it is reasonable to speculate that the hyperalgesia seen after M3G treatment is regulated 
by this system.  However, it is again notable that NTX serves as a TLR4 antagonist, abolishing 
the possibility of a role for this receptor system in studies employing NTX pretreatment 
paradigms (Li, 2012).  Indeed, it appears that NTX does not block the ability of M3G to increase 
cellular activity in the PAG (Arout, Caldwell, McCloskey, & Kest, unpublished observations) 
and therefore makes such speculation impractical.  As such findings involving TLR4 are novel, 
additional corroborative and expansive studies are required. Additionally, behavioral 
pharmacological studies investigating a role for TLR4 in M3G-induced hyperalgesia appear 
nonexistent. 
 
Although it has been suggested that M3G can be transformed back into morphine, it is entirely 
possible that morphine-induced hyperalgesia and the hyperalgesic state present after 
administration of M3G are two independent phenomena.  It has been observed that morphine 
antagonized by NTX results in a marked decrease in the number of c-Fos active neurons in the 
PAG, while mice pelleted with NTX prior to M3G administration show no such decrease in 
active neurons in this same brain region.  This suggests that M3G hyperalgesia is mediated by 
non-opioid mechanisms independent of transformation back into morphine (Arout, McCloskey, 
& Kest, unpublished data), or activity at hyperalgesia-mediating ORL1 opioid receptors (Moran 
& Smith, 2002; Rossi, Leventhal, Bolan, & Pasternak, 1997).  Nonetheless, it is still unknown 




nervous system (CNS), as all currently known opioid receptor subtypes have been excluded 
(Moran & Smith, 2002).  Other brain regions relevant to opioid pain modulation such as the 
locus coeruleus, anterior cingulate cortex, ventral tegmental area, nucleus accumbens, and 
medulla may play a significant role in morphine-induced hyperalgesia involving morphine 
metabolites and therefore require further study. 
 
Though there is an abundance of data supporting a possible role for the morphine metabolites in 
hyperalgesia, new research contradicts such speculations.  It is becoming apparent that the 
morphine metabolites, though able to elicit hyperalgesia, do so through mechanisms independent 
of the hyperalgesia seen after morphine treatment.  For example, Swartjes and colleagues (2012) 
demonstrated a negative correlation between hyperalgesia (evidenced by tail withdrawal latency) 
and blood plasma concentrations of M3G.  In fact, it was found that as plasma levels of 
morphine increased, so did the magnitude of hyperalgesia.  This evidence suggests that morphine 
itself may be the mediator in opioid-induced hyperalgesia.  In addition, MRP3-/- mice lacking the 
ability to export M3G from the liver into systemic circulation also develop hyperalgesia after an 
acute morphine injection (Swartjes et al., 2012).  Such evidence serves to eliminate the role of 
the morphine metabolites in opioid-induced hyperalgesia, leaving all roads likely pointing to the 
direct involvement of another receptor system: the NMDA receptor.  
 
4) Opioid-Induced Hyperalgesia and the N-Methyl-D-aspartate Receptor 
The NMDA receptor system has a well-studied and important role in neural and behavioral 
plasticity, long-term potentiation, learning, and memory. For these reasons, it is an excellent 




(Trujillo & Akil, 1991).  Specifically, Trujillo and Akil (1991) conducted studies indicating a 
likely role for this receptor system in the development of opioid tolerance and dependence, 
resulting from neural adaptations after repeated morphine exposure.  Accordingly, as there is an 
apparent relationship between the NMDA receptor and morphine tolerance and dependence, 
investigators became interested in the possible role of this system in morphine-induced 
hyperalgesia.  Also important is the parallel between the aforementioned dynorphin-induced 
allodynia and hyperalgesic states and morphine-induced hyperalgesia, in that both produce 
naloxone-insensitive pronociception that is blocked by NMDA receptors.  This suggests that 
opioid-induced pronociceptive states are served by the NMDA receptor system (Laughlin et al., 
1997).   
 
4a.  NMDAR distribution.  NMDA receptor expression is widespread throughout both the 
central and peripheral nervous system, and is primarily responsible for fast excitatory synaptic 
transmission in the brain.  Interestingly, it has recently been found that NMDA receptors are not 
necessarily static, and have the ability to travel from synaptic to extrasynaptic sites.  This 
apparent mobile nature of NMDA receptors is increasingly being implicated in early cognitive 
dysfunction as well as a variety of neurodengerative disorders (Gladding & Raymond, 2011).  
Though this receptor system’s most notable role to date is memory function and the control of 
synaptic plasticity, it is becoming more and more apparent that NMDA receptors also play a 
significant role in opioid-induced hyperalgesia.  This speculation is supported by the fact that 
NMDA receptors are present in particularly dense populations in areas that modulate pain 
signaling, such as the dorsal root ganglion, superficial layers of the dorsal horn laminae, 





The postsynaptic density (PSD), which is a protein dense specialization attached to the 
postsynaptic membrane, is rich in glutamate receptors.  This specialization ensures that receptors 
on the postsynaptic side are close enough to the presynaptic neurotransmitter release sites.  Here, 
NMDA receptors form a large macromolecular complex that is comprised mainly of scaffolding, 
and adaptor and effector proteins that are involved in the activation of downstream signaling 
cascades and the overall regulation of NMDA receptor function, stability, and trafficking 
(Gladding & Raymond, 2011; Kennedy, 1997).  NMDA receptors are also located in dense 
populations both peri- and extra-synaptically.  Those receptors found perisynaptically likely 
serve as mobile receptors traveling to and from the PSD, while extrasynaptic NMDA receptors 
are those found on the soma, dendrites, and spines of neurons.  Not only do these receptors 
redistribute between the PSD, peri- and extrasynaptic locations, but they also navigate between 
the plasma membrane and intracellular compartments.  Synaptic and extrasynaptic NMDA 
receptors found in the hippocampus and the cortex are associated with the activation of 
neuroprotective and apoptotic signaling cascades, respectively (Gladding & Raymond, 2011).  
Since the activation of NMDA receptors commonly results in any number of second messenger 
and other downstream signaling pathways, further in-depth research is required as it is plausible 
that one of these second-order activations could be the connecting pathway between the NMDA 
system and the initiation of morphine-induced hyperalgesia. 
 
There are seven known subunits of the ionotropic NMDA receptor; GluN1, GluN2A-GluN2D, 
and GluN3A-GluN3B, with several variants of each type of subunit.  Most common are NMDA 




receptors are found both extrasynaptically as well as synaptically (Gladding & Raymond, 2011).  
During development, GluN1 expression is at its plateau in most areas of the brain, with GluN2B 
sharing a similar pattern of developmental expression. However, GluN2B expression declines in 
adulthood, and the emergence of GluN2A is much more apparent as the hippocampus and cortex 
fully mature (Gladding & Raymond, 2011).  The synaptic target of each fully assembled NMDA 
receptor is determined by the NMDA receptor subunit composition, which is conceived during 
development.  In order to activate the ionotropic NMDA receptor complex, the binding of 
glycine and glutamate to the GluN1 and GluN2 subunits, respectively, is required.  However, to 
remove the Mg2+ block and open the channel to allow a flux of ions additionally requires 
postsynaptic depolarization.  A subsequent influx of Ca2+ through the NMDA receptor is the 
neural substrate responsible for synaptic changes seen in long-term potentiation (LTP) and long-
term depression (LTD).  However, overstimulation of this receptor system can be detrimental in 
that Ca2+ dependent proteases, lipases, and DNAases can be activated (Gladding & Raymond, 
2011). 
 
4b. NMDAR-mediated opioid hyperalgesia.  Perhaps most intriguing is the finding that 
morphine-induced hyperalgesia occurs independent of opioid receptors.  Several studies have 
indicated that morphine hyperalgesia is not a consequence of either prior or concurrent opioid 
receptor activity (Yoburn, Cohen, & Inturrisi, 1986; Juni et al., 2006; van Dorp et al., 2009; Juni, 
Cai, Stankova, Waxman, Arout, Klein, Dahan, Hruby, Mogil, & Kest, 2010).  In fact, the 
blockade of NMDA receptor activity using MK-801 in naltrexone-pelleted mice results in a 




paradigms, providing further support that this reversal is independent of opioid receptor activity 
(Juni et al., 2006; van Dorp et al., 2009). 
 
Juni et al. (2006) reported that in mice where hyperalgesia subsided after continuous infusion of 
a large dose of morphine, acute administration of a low dose of morphine immediately reinstated 
a hyperalgesic state.  In addition, hyperalgesia is evident after continuous morphine infusion in 
opioid receptor triple knock out (TKO) mice lacking all three genes encoding the prominent 
opioid receptors µ, δ, and κ (Juni, Klein, & Kest, 2006; Juni, Klein, Pintar, & Kest, 2007).  
Currently, there is no reliable consensus as to the location of specific neural substrates that 
underlie the manifestation of this hyperalgesic state.  However, there are several proposed 
mechanisms that seem to play a significant role, particularly involving the N-Methyl-D-aspartate 
receptor system. 
 
The NMDA receptor system has long been speculated to modulate opioid-induced hyperalgesia.  
However, the precise mechanism by which this receptor system may be enabling such a state 
remains quite nebulous.  It is clear from an abundance of research that NMDA receptors play a 
particular role in central sensitization and consequent inflammatory pain, although a knowledge 
base for the role it plays in peripheral sensitization is not yet established (Du, Zhou, Coggshall, 
and Carlton, 2003).  It has been found that glutamate does indeed act on unmyelinated cutaneous 
sensory axons in rodents and humans, suggesting action at the same C- and Aδ-fiber neurons that 
play a primary role in hyperalgesia.  In fact, intraplantar injections of glutamate induce both 




allodynia and hyperalgesia that is easily abolished following an injection of the antagonist MK-
801 (Du et al., 2003). 
 
As opioids do not have any binding affinity for the NMDA receptor, it is implausible that opioids 
directly interact with this receptor system.  In addition, NMDA receptor antagonists do not affect 
acute opioid analgesia, further illustrating a lack of direct interaction between opioids and the 
NMDA receptor system (Mao et al., 2002).  However, a role for the NMDA receptor in 
morphine-induced hyperalgesia is indicated by findings that this hyperalgesic state is reversed by 
the non-competitive antagonist MK-801 (Juni et al., 2006; Juni et al., 2008; Waxman et al., 
2010).  Additionally, Swartjes and colleagues (2012) attenuated hyperalgesia by administration 
of ketamine or the novel NR2B selective NMDA antagonist traxoprodil.  Such evidence provides 
a promising illustration of a role for the NR2B subunit in the development of opioid-induced 
hyperalgesia; this subunit coincidentally is particularly dense in both spinal and supraspinal sites 
such as the dorsal root ganglia, superficial layers of the dorsal horn laminae, the thalamus, 
hippocampus, and cortex (Swartjes et al., 2012).  Interestingly, physicians do not prescribe 
ketamine to counteract opioid induced hyperalgesia due to the manifestation of psychotropic side 
effects; however, traxoprodil appears to have no such effects, making it a plausible consideration 
for physicians in preventing hyperalgesia in patients undergoing opioid treatment.   
 
Several studies have indicated that exposure to morphine through intracellular protein kinase C 
(PKC) may prime NMDA receptors and cause increased excitability (L. Chen & Huang, 1992; 
Mao, Price, & Mayer, 1994; Martin, Malmberg, & Basbaum, 2001; Sluka & Audette, 2006).  




that PKC somehow modulates NMDA receptors by removing the Mg2+ block, thereby allowing 
an influx of Ca2+ (Mao et al., 2002) which subsequently further stimulates calcium-sensitive 
protein kinase, particularly the gamma isoform (PKCγ).  PKCγ catalyzes NMDA receptor 
phosphorylation, leading to augmentation of the NMDA mediated glutamate responses and to 
long-term potentiation of synaptic transmission (L. Chen & Huang, 1992; Sluka & Audette, 
2006). Coincidentally, most of the isoforms of the PKC enzyme are found in the superficial 
laminae of the dorsal horn, indicating an anatomical overlap of opioid receptors, NMDA 
receptors, and PKC activity (Sluka & Audette, 2006).  When activated in the spinal cord, PKC 
results in decreased heat and mechanical latency thresholds, increased release of glutamate, and 
sensitization of dorsal horn neurons as well as the spinothalamic tract (Sluka & Audette, 2006).  
It has been reported that development of morphine hyperalgesia is preventable by intrathecal 
administration GM1 ganglioside, an intracellular inhibitor of PKC translocation/activation.  Such 
evidence illustrates a critical role for the activity of this protein that occurs in response to NMDA 
receptor activation in morphine-induced hyperalgesia (Mao et al., 1994). 
 
4c.  Role of glutamate transporters in opioid-induced hyperalgesia.  The homeostasis of 
extracellular glutamate is regulated by the glutamate transporter (GT) system, which contains 
minimally five differentially expressed Na+-dependent GT proteins.  EAAC1 is a GT that is 
primarily expressed in neurons, while GLAST and GLT-1 are primarily found in glial cells.  
Evidence has shown that GTs play a crucial role in the prevention of glutamate neurotoxicity.  
Mao and colleagues (2002) used immunocytochemical methods, western blot analysis, and 
behavioral methods (tail-flick and paw-withdrawal tests) to illustrate that continuous morphine 




role for this system in morphine hyperalgesia.  Indeed, additional studies in various brain regions 
have demonstrated changes in GLT-1 mRNAs subsequent to naloxone-precipitated morphine 
withdrawal, and morphine tolerance is decreased after subcutaneous injection of the glial GT 
activator MS-135 (Mao et al., 2002). 
 
The most commonly proposed mechanism of morphine-induced hyperalgesia involves the 
colocalization of NMDA receptors and opioid receptors in the nervous system.  Of particular 
interest is that fact that both NMDA receptors and µ-opioid receptors are both found pre- and 
postsynaptically, and are particularly abundant in lamina I-III of the dorsal horn (Mao et al., 
2002; Gladding & Raymond, 2011).  It is hypothesized that even though opioids are reliably 
inhibitory in nature, they may somehow activate NMDA receptors.  Subsequently, continuous 
opioid administration may cause a reduction in GT function, thereby causing an increase in the 
amount of synaptic glutamate available for uptake, particularly in the spinal cord where opioids 
most commonly exert their effects.  These physiological changes, in turn, may be responsible for 
the development of both tolerance and hyperalgesia following prolonged opioid treatment.  
Indeed, Mao et al. (2002) found that levels of EAAC1 and GLAST were significantly reduced in 
lamina I, II, III, IV, V, and VI (the lowest levels in laminas III-VI) of rats receiving seven days 
of intrathecal morphine in both acute injection and continuous infusion paradigms, when 
compared to baseline levels and saline groups.  In addition, these reductions in GTs appear to be 
dose-dependent, as significant differences were seen after treatment with 10µg, and more so after 
treatment with 20µg of morphine.  Coadministration of naloxone not only prevented the 
downregulation of both EAAC1 and GLAST, but it also prevented the development of morphine 




until day six of morphine infusion and persists until minimally day eight, which corresponds well 
with the timeline of the manifestation of morphine hyperalgesia (Mao et al., 2002).  Furthermore, 
hyperalgesia in rats treated with morphine is intensified by exogenous glutamate, evidenced by 
reduced paw-withdrawal latencies and a prolonged state of hyperalgesia.  Mao and colleagues 
(2002) also found that this downregulation of GT after morphine administration is preventable if 
NMDA receptors are inhibited.  Finally, administration of GT regulators (i.e. riluzole) 30 
minutes prior to exogenous glutamate prevents the development of tolerance and/or hyperalgesia, 
but does not abolish an already-present state of tolerance and/or hyperalgesia.  When 
administered without glutamate, riluzole results in a 10-12% increase from baseline paw-
withdrawal latencies prior to onset of hyperalgesia (Mao et al., 2002).  Such evidence suggests 
that continuous morphine impacts glutamate homeostasis in the spinal cord, which in turn 
somehow induces both morphine tolerance and hyperalgesia.  Therefore, it is likely that spinal 
changes in GT activity play a role in the development of opioid tolerance and possibly morphine-
induced hyperalgesia (Mao et al., 2002).  However, the aspect of the aforementioned study 
evidencing a temporal and therefore neuroanatomical correlation between morphine analgesic 
tolerance and hyperalgesia no longer holds precedence, since more recent studies have shown 
otherwise (Juni et al., 2006).  A definitive answer as to how morphine causes hyperalgesia via 
non-opioid mechanisms that likely involve NMDA receptors in the spinal cord remains 
unknown. 
 
Though the majority of evidence supports a role for spinal NMDA receptors in morphine 
hyperalgesia, other studies have illustrated a critical role for supraspinal medullary NMDA 




hyperalgesia.  Additionally, it has been reported that bilateral lesions or lidocaine injections into 
the RVM not only reversed hyperalgesia, but also restored analgesia that had been previously 
obfuscated (Vanderah, Ossipov, et al., 2001; Vanderah, Suenaga, et al., 2001).  A role for the on- 
and off-cell system in the RVM has been proposed after evidence that the application of mustard 
oil resulted in an increase of on-cell firing.  When on-cell activation was blocked by infusing the 
NMDA receptor antagonist AP5 into the RVM, hyperalgesia was avoided.  In addition, 
secondary thermal hyperalgesia after mustard oil application was also correlated with a decrease 
in off-cell firing that was unchanged by AP5 infusion.  Thus, NMDA receptors appear to have 
two distinct roles in the RVM; they potentiate analgesia when they are recruited to activate off-
cells, while producing hyperalgesia when contributing to activation of on-cells after an acute 
inflammatory stimulus (Xu et al., 2007).  Therefore, it appears that NMDA receptor-mediated 
activation of on-cells is crtical for the development of secondary thermal hyperalgesia in an acute 
context.  Such evidence provides support beyond solely a spinal mechanism that employs the use 
of NMDA receptors in opioid-induced hyperalgesia, to include supraspinal mechanisms as well. 
 
Administration of the noncompetitive NMDA receptor antagonist MK-801 has been shown in 
various studies to block morphine hyperalgesia when given in conjunction with GT inhibitors 
(Mao et al., 2002).  Such studies have shown MK-801 to reverse and in some cases even enhance 
opioid analgesia in a sex- and dose-dependent manner (Bodnar & Kest, 2009; Juni et al., 2009; 
Waxman et al., 2009; Waxman et al., 2010).  For example, hyperalgesia induced by low 
morphine doses in both male and female mice is reversed after acute injections of MK-801, 
while hyperalgesia induced by high doses of morphine infusion is reversed by MK-801 in males 




doses of morphine, females recruit a melanocortin-1 receptor dependent system to process 
nociceptive information (Juni et al., 2009).  In addition to sex differences with regard to 
hyperalgesic responses, male and female mice also show differences in analgesia.  Studies have 
shown that the NMDA receptor antagonist MK-801 reverses stress-induced analgesia in males, 
but not females, further suggesting a role for a non-NMDAergic system in the processing of pain 
information in females (Mogil et al., 2003).  However, the locus of action of these effects is 
unknown; whether these processes are mediated by spinal mechanisms, supraspinal mechanisms, 
or substrates working collaboratively in both regions remains unclear. 
 
5) The Melanocortin-1 Receptor and Opioid-Induced Hyperalgesia 
 
5a.  Melanocortin receptor distribution.  The melanocortin (MC) receptor system has become 
the main receptor system under investigation for its role in regulating female opioid-induced 
hyperalgesia.  The receptor system is composed of five subtypes (MC1 through MC5), all of 
which are G protein-coupled receptors.  Each subtype has vastly different functions, ranging 
from pigmentation, to energy balance, to the regulation of gland functioning within mammals.  
Of particular interest in the regulation of nociceptive processing is the MC1R, which is unusually 
polymorphic with more than 60 known naturally occurring variants (García-Borrón, Sánchez-
Laorden, and Jiménez-Cervantes, 2005). The seven transmembrane MC1R is primarily 
expressed on the surface of melanocytes, or melanin-producing cells in the epidermis layer of the 
skin (Nakayama, et al., 2006).  Past in situ hybridization and immunohistochemical studies have 
revealed a widespread distribution of this receptor system in the peripheral nervous system, yet a 




and in brain glial cells.  Some reports have hypothesized the endogenous ligands for this receptor 
to be α-melanocyte-stimulating hormone (α-MSH) and adrenocorticotrophin (ACTH), which 
result in an increase in cAMP; this proopiomelanocortin gene product has been found to elicit 
inhibition of thermal pain, while contradictory studies have shown it to have an anti-opioid role 
(Xia, Wikberg, & Chhajlani, 1995; Mogil et al., 2003; Delaney et al., 2010). 
 
Several variants of the MC1R have been identified and found to have a role in hair and skin 
pigmentation, a possible role in the susceptibility to skin cancer, and finally, a likely role in 
inflammatory and pain responses via the mitigation of proinflammatory cytokines (Mogil et al., 
2003; Dessinioti, et al., 2011).  The latter function has received remarkably little attention in the 
literature, as most studies on this receptor system focus on its role in hair and skin pigmentation 
(Rana, Hewett-Emmett, Jin, Chang, Samsuughin, et al., 1998; Sánchez-Más, 2004; Mogil et al., 
2005; Nakayama, et al., 2006; Dessinioti et al., 2011; García-Borrón et al., 2005).  The bit of 
research on this receptor system that has focused on its role in pain has studied differences in 
analgesic pain responses as a function of MC1R variants (Mogil et al., 2005). 
 
5b.  Sex differences in opioid-induced analgesia and hyperalgesia.  Although research 
examining the NMDA receptor system reveals promising evidence for a solution to opioid 
induced hyperalgesia, this system cannot be entirely responsible for such a phenomenon.  
NMDA receptor antagonists do not reverse hyperalgesia across the board, as they leave 
hyperalgesia undisturbed in female CD-1 mice in some cases (Juni et al., 2008; Juni et al., 2010).  
It has been shown after continuous infusion of a low dose of morphine (1.6mg/kg/24h), 




At a high dose of morphine (40mg/kg/24h), there appears an analgesic period of two to three 
days, followed by hyperalgesia in both males and females that persists through day 11.  
Additionally, this hyperalgesic state occurs independently of prior or current opioid receptor 
activity, as all mice were concurrently treated with pellets containing the general opioid 
antagonist, naltrexone (Juni et al., 2008; Juni et al., 2010).  As such, systemic administration of 
NDMAR antagonists attenuated hyperalgesia in both sexes at a low dose, while it reversed 
hyperalgesia exclusively in males at the high dose.  After ovariectomy (OVX), females resorted 
to male-typical hyperalgesic patterns, suggesting that they do in fact possess the same systems 
but are diverted from using them by circulating ovarian hormones.  This is further evidenced in 
that when ovariectomized females are subjected to estrogen replacement, their female-typical 
hyperalgesic patterns are restored.  Therefore, it is believed that not only is there a role for 
NMDA receptor pathways in hyperalgesia, but also a hormonally regulated role for minimally a 
second receptor system (Juni et al., 2008; Juni et al. 2010). 
 
The MC1R system’s role in skin pigmentation and anti-inflammatory processes is well studied 
and understood.  What is not well characterized is this receptor system’s role in the inhibition 
and regulation of non-inflammatory pain, namely, analgesia and hyperalgesia.  However, due to 
the MC1R’s presence in the PAG, this proposed function is feasible.  Recent quantitative trait 
locus (QTL) mapping studies have directed attention to the MC1R system in terms of sex 
differences in opioid analgesia.  Specifically, the MC1R system appears to mediate κ-opioid 
analgesia in females, but not males.  Additionally, clinical use of opioids modulated by the κ-
opioid receptor is more efficacious in females than in males.  Mogil and colleagues (2003) 




they found the MC1R gene on chromosome 8 to be the most likely candidate gene to mediate 
states of female-specific analgesia.  Additionally, it was found that analgesia in females was 
completely obfuscated after administration of the κ-selective opioid antagonist nor-
binaltorpimine, even though it was given 48 hours prior to U50,488H injections.  This state of 
U50,488H analgesia is likely mediated centrally, as exclusively i.c.v. administration of MK-801 
in males reverses this κ-opioid’s analgesic state.  Finally, whereas MK-801 had no effect in 
mutant B6 female mice, mutant C57BL/6J-Mc1re/e (spontaneous mutants of the B6 background 
lacking functional MC1Rs [e/e]) mice differentiated from B6 mice only by a lack of functional 
MC1Rs, demonstrated male-like, NMDA-mediated U50,488H analgesia.  Therefore, Mogil et al. 
(2003) concluded that minimally B6 female mice are using the melanocortin system to mediate 
pain responses resulting from U50,488H administration, and QTL studies makes the contribution 
of any other protein to this process unlikely. 
 
In this same series of studies, Mogil et al. (2003) explored the effects of blocking the MC1R 
system during U50,488H administration, using the antagonist Ac-Nle-Asp-Trp-DPhe- Nle-Trp-
Lys-NH2.  They hypothesized that such activities would cause the mice to “switch” systems, in 
that they would begin using the NMDA receptor system when the MC1R system was not 
available.  Indeed, this is what occurred; U50,488H analgesia was potentiated in outbred, 
exclusively female mice after i.c.v. injection of the aforementioned antagonist that was reversed 
by injection of MK-801, demonstrating a shift in the system being used.  Similar results were 
obtained using cyclopentylglycine, another MC1R antagonist (Mogil et al., 2003). 
 




question the role of MC1R in morphine-induced hyperalgesia.  Recent studies have illustrated a 
sex difference, as female and male C57BL/6J (B6) naltrexone-pelleted mice showed 
hyperalgesia beginning on day 1 and 3, respectively, after continuous high dose morphine 
infusion.  However, only naltrexone-pelleted B6 e/e male mice showed hyperalgesia from Day 2 
to 7 (Juni, et al. 2010). Furthermore, MK-801 reversed hyperalgesia in B6 and CD-1 males but 
not in B6 or CD-1 females.  A selective MC1R antagonist, MSG606, reversed hyperalgesia in B6 
and CD-1 females but not in B6 or CD-1 males, all undergoing continuous infusion of the high 
dose of morphine.  Conversely, continuous infusion of a low dose of morphine caused 
hyperalgesia in both e/e males and females (Juni, et al. 2010), thus further illustrating the 
involvement of a number of neural substrates in morphine-induced hyperalgesia.  
 
Juni et al.’s (2010) findings reveal a striking counterpart to Mogil et al.’s (2003) rodent and 
clinical findings, in that these newer findings supported the idea that κ-opioid analgesia, and now 
morphine-induced hyperalgesia, is mediated by NMDA receptors in males and MC1Rs in 
females.  Furthermore, it is likely that hyperalgesic mechanisms are located supraspinally as 
MC1Rs have been found to be expressed particularly in the midbrain PAG, a region critical to 
pain modulation (Juni et al., 2010).  Noted, however, is the fact that these findings are restricted 
to a high dose of morphine and that similar findings are not yielded by low morphine infusion 
doses, thus suggesting minimally two distinct neural networks responsible for morphine 
hyperalgesia.  This is further evidenced by aforementioned findings that although both male and 
female hyperalgesia are reversed by MK-801 after infusion of a low dose of morphine, female 
hyperalgesia begins later and lasts several infusion days, if not weeks, longer than males (Juni, et 





Interestingly, it has been demonstrated that in the absence of functional µ-opioid receptors, 
morphine analgesia is regulated by κ-opioid receptors.  This effect is minimal at low doses, but 
quite remarkable at high doses of morphine.  Such evidence suggests minimally an interaction 
between µ- and κ-opioid receptors in morphine analgesia, which may indicate a role for this 
interaction in hyperalgesia as well (Yamada, et al., 2006).  However, such studies were 
confounded by possible inadequate morphine doses and therefore are preliminary.  Together, 
these studies indicate that NMDA receptors mediate hyperalgesia during a low morphine dose in 
male and female mice, whereas MC1Rs and NMDA receptors respectively play a role in female 
and male hyperalgesia during infusion of the high morphine dose.  Thus, this demonstrates a 
critical role for the MC1R system in female opioid-induced hyperalgesia.  However, beyond the 
aforementioned data, little is known as to the precise location and further mechanism of action of 
how MC1Rs mediate female opioid-induced hyperalgesia, as MSG606 was administered through 
a single systemic bolus injection and not directly into a specific site of the central nervous system 








As demonstrated in the aforementioned literature review, the neural substrates underlying opioid-
induced hyperalgesia remain unknown and require further investigation.  Elucidating the precise 
mechanisms and corresponding locations underlying opioid-induced hyperalgesia is imperative, 
as morphine remains the most effective pharmacological intervention for the treatment of 
moderate to severe pain.  This paradoxical state of sex- and dose-dependent hyperalgesia creates 
the most prominent and serious barrier to successful treatment.  The next section will provide 
general background regarding the rationale for the experimental methods chosen, followed by a 
description of the specific studies conducted and hypotheses regarding expected findings. 
 
Rationale for the Use of Continuous Morphine Infusion 
Opioids are widely used analgesics, and to date, morphine is still the most highly efficacious and 
widely used treatment for moderate to severe pain (Inturrisi, 2002).  It is for this reason that 
morphine was chosen as the main opioid agonist for study in this dissertation.  Although chronic 
infusion is the most clinically relevant paradigm for morphine administration, methods 
employing repeated injection/oral administration might allow for hyperalgesia resulting from 
withdrawal due to interruptions in treatment.  Our paradigm uses continuous, uninterrupted 
delivery, which eliminates this confound.  Obtaining an understanding of the hyperalgesic 
liabilities following continuous morphine exposure can provide a substantial and important 
scientific contribution to the field. 
 




 My studies require continuous infusion of opioids into healthy subjects.  Clearly, this is not 
possible in human populations.  Furthermore, multiple genetic and environmental factors may 
confound the study of hyperalgesia in this population.  These considerations are irrelevant in 
laboratory-obtained rodents.  For this dissertation, mice were chosen as subjects because of the 
large body of literature documenting pain related characteristics in the mouse, the high degree of 
genetic similarity with human beings, and the ready availability. 
 
Rationale for Investigating Different Routes of Administration for Antagonists 
The morphine studies described in this dissertation utilized two central routes of antagonist drug 
administration.  Systemic administration results in widespread distribution along the neuraxis 
and periphery, leading to activation at spinal, supraspinal, and peripheral levels, sites which are 
too diffuse to pinpoint a precise locus of action in the central nervous system.  Therefore, more 
focal administration paradigms of intracerebroventricular and intrathecal administration were 
utilized in order to assess distinctly supraspinal and spinal loci contributions to morphine-
induced hyperalgesia, respectively. 
 
Rationale for Selected Experimental Assay of Nociception 
Multiple experimental assays have been developed for use with both animals and humans to aid 
in the assessment of nociception.  These measures typically employ vastly different techniques 
and investigate distinct modalities such as thermal pain, mechanical pressure, noxious chemicals 
or nerve injury.  As these measures assess pain as a result of vastly different evocation and 
presumably underlying physiological mechanisms, Mogil and colleagues (1999) conducted a 




12 common measures of nociception and later identified three clusters of pain tests which appear 
to share common genetic substrates and presumably underlying physiology (Mogil et al., 1999a, 
1999b). The extensive analysis revealed three major clusters of nociception: “thermal 
nociception” (Hargreaves’ test, hotplate test, tail-immersion withdrawal test, and autotomy), 
“chemical nociception” (acetic acid abdominal constriction, magnesium sulfate abdominal 
constriction, and both the acute- and tonic-phases of the formalin test), and “mechanical 
hypersensitivity” (von Frey test, carrageenan thermal hypersensitivity, peripheral nerve injury, 
and mechanical hypersensitivity).  Mogil and colleague’s (1999a, 1999b) findings argue for a 
multiaxial approach to the study of pain, whereby stimulus modality and genetic background 
should play primary roles, while other factors such as the site or duration of noxious stimuli, 
neuropathy, or inflammation seem to be of limited relevance.  
 
Studies of nociception are further limited by the specificity of the nociceptive process under 
investigation.  For example, some of the most common techniques for studying pain sensitivity 
include measures of behavioral changes following exposure to high temperatures, nerve ligation, 
mechanical compression, or inflammation.  Not only do these measures differ in modality, but 
they also show little commonality in their response to pharmacologic intervention (Lai, Ossipov, 
Vanderah, Malan, Jr., & Porreca, 2001) and may even be modulated by different genes (Mogil, 
1999).  Thus, an organism’s responses to one measure of thermal pain may have little bearing on 
its responses to noxious mechanical or inflammatory stimuli.  This makes comparisons between 
studies especially difficult, as it demands congruence of the nociceptive modality.  Additionally, 
such measures in themselves would likely serve as confounds for the proposed series of studies, 





For the present studies, a measure of nociception is required that is valid, reliable, non-invasive, 
and could be easily repeated in a within-subjects design that includes repeated testing of the 
same animals carried out over a short period of time (less than two hours). To address these 
concerns, all of the proposed sets of studies described within this dissertation employed one 
experimental nociceptive assay, the tail withdrawal test. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
The tail withdrawal assay: The tail withdrawal assay is a well-known measure of nociceptive 
sensitivity based on phasic, reflexive limb withdrawal from a noxious stimulus.  Although first 
described using rats exposed to a focused light beam (D'Amour & Smith, 1941), various 
modifications of this procedure have been utilized over the years to objectively assess animal’s 
sensitivity to noxious stimulation.  A modified version of this classic test was selected for the 
current proposed dissertation (Janssen, Niemegeers, & Dony, 1963), based on its minimally 
invasive nature and its stability and reliability in the context of repeated testing (Wilson & 
Mogil, 2001).  The assay involves immersing the distal portion of the animal’s tail into a hot-
water bath and measuring the latency, in seconds, between water immersion and reflexive 
withdrawal of the tail.  For the experiments discussed in the current proposed dissertation, 
latency of tail-withdrawal from the hot-water bath was used as the dependent measure to reflect 
nociceptive sensitivity. 
 
The underlying physiological mechanism involves the heat of a hot-water bath activating 
nociceptors in the distal half of the animal’s tail, which transduce the impending damage into a 




located in the dorsal root ganglion (Yeomans & Proudfit, 1996).  Those neurons within the 
dorsal root ganglion extend their connections to the dorsal horn of the spinal cord where they 
synapse onto local interneurons and on projection neurons. These signals are then sent via 
sensory afferents primarily to the brain stem, thalamus and hypothalamus (Hanai, 1998). Back 
near the site of initiation, local neurons in the dorsal horn process efferent regulatory nociceptive 
inputs, leading to activation of the autonomic nervous system and motor neurons mediating local 
withdrawal reflexes (Y. P. Chen, Chen, & Pan, 2005). Regulation of the phasic tail withdrawal 
can therefore occur via modulation of either peripheral or central mechanisms (McCormack, 
Prather, & Chapleo, 1998). 
 
Rationale for Specific Aims of the Present Dissertation 
Morphine hyperalgesia is reversed in a sex- and dose-dependent manner in male and female mice 
(Juni et al., 2010).  Whereas the NMDA receptor antagonist MK-801 reverses hyperalgesia in 
males, and females receiving a low dose of morphine, the melanocortin-1 receptor antagonist 
MSG606 conversely reverses morphine hyperalgesia exclusively in females receiving a high 
dose of morphine.  In Juni et al. (2010), these drugs were injected systemically, thus the location 
of the neural mechanisms contributing to morphine hyperalgesia, whether they are spinal or 
supraspinal, is unknown.  The goal of this dissertation is to further investigate the mechanisms 
underlying morphine-induced hyperalgesia, specifically regarding the potential central sites of 
action of this phenomenon.  Accordingly, the aforementioned findings are subjected to 
replication with additional exploration of possible spinal and supraspinal involvement in the 





The goal of Specific Aim 1 was to evaluate whether or not supraspinal sites contribute to 
morphine hyperalgesia.  We aim to investigate the role of the NMDA and melanocortin-1 
receptor systems in morphine hyperalgesia, using antagonists of these substrates injected directly 
into the lateral ventricles (intracerebroventricular injections; i.c.v.).  As previous research has 
been limited to systemic administration (Juni et al. 2010), performing such proposed studies will 
allow us to further examine the specific supraspinal regions in the central nervous system 
relevant to this hyperalgesic state.  We hypothesize that hyperalgesia evoked by low doses of 
continuous morphine infusion will be reversed by i.c.v. injections of the NMDAR antagonist, 
MK-801, in both males and females.  Conversely, we believe that following high doses of 
continuous morphine infusion, while males will continue hyperalgesic mediation by the 
NMDAR system, female-specific hyperalgesia will be reversed exclusively by i.c.v. injections of 
the MC1R antagonist MSG606.  Assuming that the findings of these studies support our 
hypotheses, a second series of studies will entail investigation of these same proposals at a spinal 
level. 
 
The goal of Specific Aim 2 was to evaluate whether or not spinal mechanisms contribute to 
morphine hyperalgesia. We aim to assess if either, neither, or both aforementioned antagonists 
work via the spinal cord (intrathecal injections; i.t.) to reverse morphine hyperalgesia.  When 
combined with the findings from Specific Aim 1, such studies will help us determine if the 
neural substrates for morphine hyperalgesia are present in both the brain and spinal cord.  We 
propose that at low doses of continuous morphine-induced hyperalgesia, this state will be 
reversed exclusively by spinal injection of the NMDAR antagonist, MK-801, in males and 




use the NMDAR system to modulate morphine-induced hyperalgesia. However, we are 
particularly interested in investigating the spinal pathways associated with the melanocortin-1 
receptor, as the literature on this receptor and its general neuronal network is scarce, suggesting 
minimal presence in spinal loci.  The anatomy of this receptor system in the spinal cord as it 
relates to MSG606 is of particular interest, as we hypothesize that hyperalgesia elicited by high 
doses of morphine infusion in females may not be reversed by this antagonist.  These findings, 
combined with the findings from Specific Aim 1, will lead to our third investigation.  
Specifically, as there are distinct sex differences in continuous morphine-induced hyperalgesia, 
we will further investigate the contribution of female hormones to this state. 
 
The goal of Specific Aim 3 was to assess hormonal contributions to sex differences evident 
in morphine hyperalgesia. We have previously shown that morphine hyperalgesia is sex- and 
dose-dependent; it is reversed in males by NMDA receptor antagonists, while this same effect is 
purportedly obfuscated in females because their ovarian hormone production (Juni et al. 2008, 
2010). However, the reversal of hyperalgesia in females mirrors the male model after 
administration of melanocortin-1 receptor antagonists, suggesting a role for this receptor system 
in morphine hyperalgesia as well (Juni et al. 2010). The present dissertation further investigated 
such claims with the use of ovariectomized females who were later subjected to hormone 
replacement using acute progesterone.  We hypothesize that intact males will continue using the 
NMDAR system to modulate continuous morphine-induced hyperalgesia, and that removing 
circulating ovarian hormones in females will cause them to “switch” systems to mirror male 
patterns.  However, following acute subcutaneous progesterone replacement, we propose that 




differences in morphine-induced hyperalgesia are a result of the presence of female hormones 
rather than a lack of male hormones, it is quite possible that progesterone administration in intact 






I. GENERAL METHODS 
 
1. Approval: 
All procedures were approved by the College of Staten Island/City University of New York 
Institutional Animal Care and Use Committee and conform to guidelines of the International 
Association for the Study of Pain. 
 
2. Subjects: 
All of the experiments described in this dissertation were performed using mice.  All mice were 
maintained on a 12:12-hour light/dark cycle in a climate-controlled room with free access to food 
(Purina chow) and tap water.  Each subject was used once unless otherwise noted in the methods, 
and for all groups, n ≥ 8.  
 
CD-1 mice – Adult CD-1 mice were obtained commercially (Charles Rivers, Kingston, NY). 
 
3. Surgical Procedures: 
Where indicated, female mice were subjected to ovariectomy (OVX) surgery through a single 
ventral midline incision. The fallopian tubes were then exposed and ligated with surgical silk 
proximal to the ovaries before removing the distal ends (including the ovaries and surrounding 
ovarian fat).  Incisions were closed using surgical silk sutures (3-0) and mice were allowed a 20-
day recovery period before undergoing any testing manipulations. This surgical procedure is a 




prevent estrogen expression and subsequent circulation (Cohen & Milligan, 1993).   
 
4. Drugs: 
Morphine – Morphine was gifted by the National Institute of Drug Abuse (Rockville, MD) was 
delivered in a 0.9% physiological saline vehicle. 
 
Naltrexone – In order to block opioid receptors and to control for any confound related to opioid 
analgesia and/or corresponding withdrawal, the opioid receptor antagonist naltrexone was co-
administered for all studies in this dissertation.  Pellets containing 30 mg of drug were obtained 
from the National Institute of Drug Abuse (Rockville, MD) and surgically implanted 
subcutaneously (see below). 
 
MK-801 - A non-competitive NMDAR antagonist, MK-801 was obtained from Sigma-Aldrich 
(St. Louis, MO) and delivered in a 0.9% physiological saline vehicle. 
 
MSG606 – A selective MC1R antagonist, MSG606 (Cyclo-[(CH2)3CO-Gly-His-DPhe-Arg-D-
Trp-Cys(S-)]-Asp-Arg-Phe-Gly-NH2), is a potent and novel cyclic thioether peptide.  It was 
synthesized in the laboratory of Victor J. Hruby, Ph.D. (Regents Professor, Department of 
Chemistry, University of Arizona, Tucson, Arizona) and provided as a gift.  It was dissolved in a 
saline and 10% dimethyl sulfoxide vehicle.  For a complete explanation of the synthesis of this 
compound, please see Juni et al., 2010. 
 




hormone involved in the female menstrual cycle, pregnancy, and embryogenesis of humans and 
mice, along with other species.  It was chosen because it has been shown that the hormone 
replacement-regulated reversal seen in past studies (Juni et al., 2008) is likely attributable to 
concentrations of progesterone produced by estrogen replacement therapy.  Specifically, this 
compound has been shown to be sufficient to acutely reinstate female-typical patterns of 
morphine-related pain responses (Waxman et al., 2010).  It was obtained from Sigma-Aldrich 
(St. Louis, MO) and delivered in a commercial sesame oil vehicle. 
 
5. Drug Delivery Mechanisms: 
Pellet implantation – NTX pellets containing 30mg of drug were wrapped in a sterile nylon 
mesh and subcutaneously implanted into the nape of the neck under oxygen/isofluorane inhalant 
anesthesia, through a small incision and closed with stainless steel surgical staples.   
 
Continuous administration paradigms – Throughout this dissertation, morphine administration 
paradigms involved continuous infusion.  Osmotic pumps (Alzet Model 2001, Alza, 
MountainView, CA) were implanted subcutaneously via the same dorsal midline incision created 
for pellet implantation.  Pumps, which dispense 1.0 microliter/hour for up to seven days and thus 
control for withdrawal commonly seen with the use of acute injection paradigms, were filled 
with either 2mg/ml or 50mg/ml of morphine (1.6mg/kg/24h or 40mg/kg/24h, respectively), and 
implanted 24 hours after naltrexone pellets. The incision was closed with a small stainless steel 
surgical clip.  Muscle, tissue, or bone was not disturbed.  
 




MC1R antagonists and their corresponding control groups involved intracerebroventricular 
(i.c.v.) or intrathecal (i.t.) injections. The NMDAR antagonist MK-801 was dissolved in 0.9% 
saline solution, while the MC1R antagonist MSG606 was dissolved in a 10% dimethyl sulfoxide 
(DMSO) vehicle.  As a vehicle control condition for the MK-801-injected groups, a solution of 
0.9% saline was used.  Serving as a vehicle control condition for the MSG606-injected groups, a 
solution of 10% DMSO/90% saline was used.  Intracerebroventricular injections were made into 
the lateral ventricles using the method of Haley and McCormick.  Specifically, a small midline 
incision was made in the scalp of mice under oxygen/isoflourane inhalant anesthesia, and lambda 
located. Injections (5 µl volume) were made directly through the skull at a point 2mm rostral and 
lateral to lambda at a depth of 3mm using a 10-µl Hamilton micro-syringe fitted with a 27-gauge 
needle. A stainless steel wound clip was used to close the incision after each injection.  
Intrathecal injections (2 µl volume) were performed under light oxygen/isoflurane inhalant 
anesthesia using a 10-µl Hamilton micro-syringe fitted with a 27-gauge needle and administered 
by lumbar puncture (adapted from Hylden and Wilcox, as cited in Li & Clark, 2002). 
Progesterone was dissolved in a sesame oil vehicle and administered via a subcutaneous bolus 
injection. The volume of drug for subcutaneous injections was administered based on the 
animal’s weight in kilograms, according to formula of 10ml drug solution per kg of mouse 
weight. 
 
6. Nociceptive Assay: 
All testing was performed following an acclimation period of at least 1 week to the local 
vivarium, and was conducted when the mice were between 6 and 10 weeks of age.  On the days 




hour before any procedures were performed.  All experiments were conducted near mid-
photophase to reduce circadian effects on nociception (Kavaliers & Hirst, 1983). 
 
Warm water tail withdrawal – The modified version of the tail-withdrawal test of D'amour and 
Smith (1941) was chosen for its stability in the context of repeated testing (Elliott, Kest, Man, 
Kao, & Inturrisi, 1995; Kest, Hopkins, Palmese, Adler, & Mogil, 2002; Nemmani & Mogil, 
2003). Studies described in this dissertation were performed with a water temperature of 47.5° C, 
since in pilot studies baseline latencies of 9–10 seconds were consistently obtained, thus 
minimizing the possibility of floor effects during hyperalgesia.  Nociception was tested near mid-
photophase to reduce possible circadian effects on nociception (Kavaliers & Hirst, 1983).  
Nociception was always assessed prior to any surgical procedure.  Animals with tails that were 
visibly injured or otherwise deformed or diseased were excluded from the study, given their 
likely effect upon peripheral pain processing in the tail.  Likewise, animals that showed obvious 
signs of disease, motor impairment, or failed to exhibit the tail withdrawal response during 
baseline behavioral assessments (withdrawal latencies exceeding 30s), were not included for 
further analysis.  Finally, animals that demonstrated motor impairments following i.c.v. or i.t. 
injections were not included in final data analyses. 
 
Animals were brought into the testing facility at least 1 hour before any testing was performed to 
afford them time to acclimate to the room conditions.  Each mouse was then wrapped snugly in a 
terry-cloth pouch so that only its tail protruded.  The animal was then lowered so that the distal 
third of its tail was immersed in a water bath maintained at 47.3°C ± 0.2° by an immersion 




withdrawal of the tail was measured twice to the nearest hundredth of a second, with each 
determination separated by at least 30 seconds to ensure adequate recovery time between 
assessments.  The 2 measures were then averaged.  A 30s cutoff latency was employed to 
prevent possible tissue damage.  Ambient room temperature for all assessments trials was at 22-
23 °C, as it has been documented that changes in tail skin temperature can affect tail withdrawal 
latencies (Tjolsen & Hole, 1993).  
 
7. Data analysis 
Chronic opioid infusion hyperalgesia was expressed as raw withdrawal latencies. Withdrawal 
latencies were analyzed using three-way analyses of variance (sex * antagonist drug * time) 
followed by a Fisher’s LSD (protected t-test) for post-hoc comparisons. P-values < 0.05 were 
considered significant. Data from low- and high-dose morphine studies were analyzed 
separately, as were data from studies employing intracerebroventricular versus intrathecal 






SPECIFIC AIM ONE: 
The contribution of supraspinal receptor sites to morphine-induced hyperalgesia 
1. INTRODUCTION 
At the forefront of clinical treatment for moderate to severe pain lies morphine; however, 
unwavering successful treatment with this opioid is complicated by the manifestation of 
hyperalgesia (Woolf, 1981; Crain & Shen, 2001; Vaughan & Connor, 2003; Chieng, Hallberg, 
Nyberg, & Christie, 2005; Galeotti, Stefano, Guarna, Biacnhi, & Ghelardini, 2006; van Dorp, et 
al., 2009).  While clinicians are concerned solely with relieving hyperalgesia in their patients, 
scientific investigators are focusing on uncovering the mechanism by which hyperalgesia 
manifests, such that more efficacious treatment options can be studied.  Delineating the receptor 
system by which hyperalgesia is regulated is at the forefront of importance in terms of pain 
treatment with morphine.  Earlier studies have insisted direct mediation by the opioid receptor 
system and have linked hyperalgesia to tolerance and withdrawal (Vanderah et al., 2001a; 
Ossipov et al., 2003); however, more recent evidence suggests oppositional results (Juni et al, 
2006).  Specifically, Juni et al. (2006) demonstrated that this paradoxical state occurs 
independently of opioid receptors, and is distinct from both withdrawal and tolerance.  A finding 
that further complicates elucidating morphine-induced hyperalgesia (MIH) is the fact that there 
exists a dose- and sex-dependent interaction.  That is, lower infusion doses of morphine render 
mice immediately hyperalgesic, a state which is reversed by an acute bolus subcutaneous 
injection of the NMDAR antagonist MK-801.  Higher infusion doses of morphine elicit analgesia 
(which is blocked by NTX), followed by a period of hyperalgesia that is reversed exclusively in 




morphine infusion exhibit hyperalgesia that is reversed exclusively by the MC1R antagonist 
MSG606 (Juni et al., 2008, Juni et al., 2010).  Such findings suggest several distinct mechanisms 
involved in the initiation and maintenance of MIH. 
 
The wide variance of experimental procedures utilized in studies of MIH makes determining the 
exact mechanism and loci by which this state is mediated quite difficult.  Along with various 
dosing and administration paradigms and the investigation of several species models, a great deal 
of the literature studies hyperalgesia as a result of nerve injury or neuropathic pain.  Thus, the 
resulting hyperalgesia may or may not be neuroanatomically, neurophysiologically, or 
neurochemically the same as hyperalgesia evoked by opioid treatment.  Finally, it is often 
assumed that the hyperalgesia seen in concomitance with opioid withdrawal is one in the same 
with all states of MIH.  While our lab has previously shown that this is not the case (Juni et al., 
2006), former studies investigated the involvement of receptor systems manipulated by 
antagonists that were injected systemically using subcutaneously bolus injections (Juni et al., 
2008; Juni et al., 2010), allowing for general distribution throughout both the peripheral and 
central nervous system.  Additional studies that investigated the role of these non-opioid receptor 
systems employed acute paradigms (Waxman et al., 2010; Waxman et al., 2012).  Such 
methodologies allowed us to determine the receptor systems that mediate MIH, but do not permit 
us to adequately extrapolate information regarding the precise location that mediates this 
troubling phenomenon.  Thus, whether the location of the neural mechanisms contributing to 





There is substantial evidence in the literature to support a significant contribution of supraspinal 
loci to the development and maintenance of hyperalgesia.  Supraspinal sites that are rich in, and 
activated by opioid receptors yield many descending inhibitory projections.  Generally, studies 
have shown significant levels of opioid receptor mRNA in cortical, diencephalic, and brainstem 
regions (Quirion, 1984).  While opioid receptors can be found in numerous supraspinal areas 
including the frontal cortex, hippocampus, thalamus, and hypothalamus, the PAG and RVM are 
most commonly associated with MIH and share reciprocal connections in terms of their role in 
nociceptive processing (Quirion et al., 1983; Quirion, 1984; Ossipov, 2004).  Specifically, it is 
hypothesized that hyperalgesia likely begins in the PAG, where excitation of opioid receptors in 
turn excites neurons in the RVM.  In addition to dense reciprocal connections with the RVM, the 
PAG is also heavily entwined with the hypothalamus and limbic forebrain structures including 
the amygdala, anterior cingulate cortex, and medial prefrontal cortex (Heinricher, Tavares, Leith, 
& Lumb, 2009). 
 
The PAG-RVM system has been shown to play a large role in inhibitory control and functions to 
suppress nociceptive inputs, thus propitiating pain (Morgan, Whittier, Hegarty, & Aicher, 2008).  
While opioids initially activate neurons in the PAG, these projections directly communicate with 
the RVM, resulting in excitation (Basbaum, Clanton, & Fields, 1978; Basbaum & Fields, 1978, 
1984).  The RVM also receives input from several other supraspinal areas, and thus is a critical 
region to bidirectional nociceptive modulation. Additionally, specialized “on”, “off”, and 
“neutral” cells in the RVM are considered to be the neural basis for the bidirectional control of 
this site in nociception (Fields & Heinricher, 1985; Fields, Heinricher, & Mason, 1991; 




Ossipov et al., 2004).  With a documented role in antinociception, it has more recently been 
proposed that in addition to suppressing pain, this system may also facilitate nociception by way 
of on-cells mediating the majority of descending facilitative information (Heinricher et al., 2009; 
Neubert et al., 2004). 
 
Aforementioned increases in the activation of on-cells in the RVM, the activation of NK-1 
receptors, and the increased release of excitatory neuropeptides (including cholecystokinin; 
CCK) bring into play a role for NMDA receptors at the supraspinal level.  At the supraspinal 
level, the importance of NMDA receptors in areas such as the RVM and PAG in acute morphine-
induced hyperalgesia has been confirmed by past studies in our lab (Waxman, 2012); however, 
their role in MIH remains unknown.  It is possible that opioids elicit hyperalgesia through RVM 
activity, inducing neuroplastic changes (Vanderah, Suenaga, et al., 2001). Evidence demonstrates 
that the NMDA receptors may have both direct and indirect involvement in this descending 
information, and additionally in these neuroplastic changes.  Specifically, inhibition of medullary 
NMDA receptors or of nitric oxide synthase weakens somatic and visceral hyperalgesia 
(Coutinho et al., 2001; Urban & Gebhart, 1999).  Changes in the excitability of the RVM have 
been observed during inflammatory hyperalgesia, and are likely a result of changes in NMDA 
receptor activation (Guan, Terayama, Dubner, & Ren, 2002; Terayama, Dubner, & Ren, 2002). 
 
Additionally, activation of NK-1 receptors in the RVM augments excitability of on-cells, evoked 
by NMDARs (Budai et al., 2007).  Furthermore, NK-1 receptors have been found to coexist with 
NMDA receptors on a subset of neurons in the RVM.  These findings suggest that substance P 




enhancing their presynaptic response, or by enhancing responses of on-cells to these excitatory 
amino acids (Budai et al., 2007).  Thus, activation of NK-1 and NMDA receptors localized to the 
RVM, paired with the subsequent sensitization of on-cells may contribute to the development of 
central sensitization hypothesized in MIH.  Additionally, efferent influences resulting from the 
release of excitatory peptide neurotransmitters such as CCK may also underlie supraspinal 
involvement in MIH, by way of indirectly activating NMDA receptors.  Specifically, both acute 
and chronic morphine treatment has been found to cause a dose-dependent increase of CCK 
activity in the RVM and the PAG (Ding & Bayer, 1993; Rosen & Brodin, 1989).  Collectively, 
the finding that NMDAR blockade at the supraspinal level completely abolishes acute morphine-
induced hyperalgesia, it is likely that the activities of the RVM and PAG that directly and 
indirectly involve supraspinal NMDA receptors may have a greater contribution to MIH than 
NMDA receptors in the spinal cord. 
 
The current study uses morphine infusion pumps in mice pretreated with NTX pellets.  This 
protocol allows for investigation of the mechanisms involved in morphine-induced hyperalgesia 
not confounded by initial states of analgesia, and additionally eliminates the possibility of opioid 
receptor involvement.  Furthermore, although morphine-induced hyperalgesia has been 
demonstrated in chronic paradigms that employ repeated injection (Ammon-Treiber & Hollt, 
2005; Suzuki, Porreca, & Dickenson, 2006), it is believed that in the context of discontinuous 
morphine delivery (i.e. multiple injections) hyperalgesia may be intensified by “mini 
withdrawal” episodes (Gutstein, 1996; Angst et al., 2003; Ossipov et al., 2004).  As opioid 
withdrawal-induced hyperalgesia has been shown to be mechanistically distinct from the opioid-




use of osmotic pumps for morphine infusion eliminates the possible occurrence of withdrawal by 
providing uninterrupted, constant morphine exposure over several days.  Indeed, past research 
using continuous infusion protocols (Vanderah et al., 2001a; Xie et al., 2005; Juni et al., 2006) 
also uncovered hyperalgesia that was hypothesized to be unassociated with withdrawal. 
 
The goal of the present study is to further investigate the potential supraspinal mechanisms 
underlying morphine-induced hyperalgesia.  Accordingly, aforementioned findings (Juni et al., 
2008; Juni et al., 2010) are subjected to replication with additional exploration of supraspinal 
involvement in the regulation of morphine hyperalgesia.  We aim to investigate the role of the 
NMDARs and MC1Rs in morphine hyperalgesia using antagonists of these receptor systems 
administered directly into the lateral ventricles via i.c.v. injection.  As previous research has been 
limited to systemic administration (Juni et al. 2010), performing these studies will allow us to 
further examine the specific neural networks specific to supraspinal loci relevant to this 
hyperalgesic state.  We hypothesize that hyperalgesia evoked by low doses of continuous 
morphine infusion will be reversed by i.c.v. injections of the NMDAR antagonist, MK-801, in 
both males and females.  Conversely, we believe that following high doses of continuous 
morphine infusion, while males will continue hyperalgesic mediation by the NMDAR system, 








Adult male and female CD-1 mice (Charles Rivers, Kingston, NY), six to ten weeks of age, were 
housed in cages of four with same-sex littermates.  All mice were maintained on a 12:12-hour 
light/dark cycle in a climate-controlled room (22 °C ± 2°C) with ad lib access to food and 
filtered tap water.  Each subject was used once.  For all conditions, n ≥ 8. 
Drug Delivery 
Twenty-four hours prior to initiation of morphine administration (labeled “day -1”), naltrexone 
pellets were subcutaneously implanted.  One day later (labeled “day 0”), continuous morphine 
treatment of two distinct dosing paradigms was introduced via subcutaneous osmotic pump 
implantation. One group received a low dose of morphine (2mg/ml, yielding a cumulative dose 
of 1.6mg/kg/24h), whereas a second group received a high dose of morphine (50mg/ml, yielding 
a cumulative dose of 40mg/kg/24h).   When mice were rendered hyperalgesic (day 4), 
intracerebroventricular injections of MSG606 (1.5 mg/ml), MK-801 (.05 mg/kg), the MSG606 
control, or the MK-801 control were performed under oxygen/isoflurane inhalant anesthesia.  
Injections (5µl volume) were made directly through the skull at a point 2mm rostral and lateral to 
lambda at a depth of 3mm using a 10µl Hamilton micro-syringe fitted with a 27-gauge needle. A 
stainless steel wound clip was used to close the incision after each injection. 
Nociceptive Assay 
The warm-water tail-withdrawal test, as described in detail above in the General Methods 
section, was chosen to assess nociception. This measure has repeatedly been shown to be stable 
and reliable in the context of recurrent testing (Elliott et al., 1995; Kest et al., 2002; Nemmani et 
al., 2004).  Each subject was tested prior to NTX pellet implantation as a baseline measure, and 




following pump implantation to assess hyperalgesia.  Finally, after intracerebroventricular 
injection of each group’s respective treatment, each mouse was tested at 15, 30, 45, and 60 
minutes to assess a time course of possible hyperalgesia reversal. 
Data Analysis 
Opioid-induced hyperalgesia was expressed as raw withdrawal latencies. Withdrawal latencies 
were analyzed using three-way analyses of variance (Sex * Drug * Time) followed by a Fisher’s 
LSD (protected t-test) for post-hoc comparisons. Data from low- and high-dose morphine studies 
were analyzed separately.  P-values < 0.05 were considered significant. Values reported are 
mean ± SEM. 
3. RESULTS 
Study 1: Hyperalgesia in males and females during continuous low-dose morphine infusion 
All subjects were rendered significantly hyperalgesic by day 4 of continuous low-dose morphine 
administration (1.6 mg/kg/24h) after concomitant treatment with NTX, as assessed using the 
warm water tail-flick withdrawal assay.  Following a baseline measure on day 4, both males and 
females were injected via the i.c.v. route with an acute dose of MSG606, MK-801, a DMSO + 
saline vehicle control for MSG606, or a saline-only vehicle control for MK-801 and tested every 
15 minutes post-injection for one hour. 
 
Significant reversal of morphine-induced hyperalgesia after injection of the NMDA receptor 
antagonist MK-801 was already evident in both sexes at 15 minutes post-injection, and persisted 
throughout the entire one-hour testing period (Figure 1A-B).  However, no such effect was 




hyperalgesia was observed in either sex following injection of either control, indicating no effect 
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Figure 1A-B.  Time course of hyperalgesia in CD-1 females (1A) and males (1B) receiving 
continuous low-dose morphine infusion, as assessed by the tail-withdrawal test. Mice were 
implanted with NTX pellets (30 mg) on day -1, and implanted with morphine pumps containing 
a low dose of morphine (1.6 mg/kg/24h) on Day 0.  When hyperalgesic (day 4), mice were 
administered acute i.c.v. injections of one of the following: the NMDA receptor antagonist MK-
801 (.05mg/kg), the MC1R antagonist MSG606 (1.5 mg/ml), the MK-801 control, or the 
MSG606 control.  After which, all mice were assayed for nociception every 15 minutes for one 
hour.  Values represent mean tail-withdrawal latency ± S.E.M.; following antagonist injections at 
“0”, significant increases in withdrawal latencies relative to baseline values obtained on day 4 
are indicated (+), denoting significant reversal of hyperalgesia assessed at 15, 30, 45, and 60 







Study 2: Hyperalgesia in males and females during continuous high-dose morphine infusion 
All subjects were rendered significantly hyperalgesic on day 4 of continuous high-dose morphine 
administration (40 mg/kg/24h) after concomitant treatment with NTX, as assessed using the 
warm water tail-flick withdrawal assay.  Following a baseline measure on day 4, both males and 
females were injected via the i.c.v. route with an acute dose of either MSG606, MK-801, 
MSG606 vehicle control, or MK-801 vehicle control, and tested every 15 minutes for one hour. 
 
Significant reversal of morphine-induced hyperalgesia after injection of the NMDA receptor 
antagonist MK-801 was already evident in exclusively males at 15 minutes post-injection, and 
persisted throughout the entire one-hour testing period (Figure 2B).  In solely females, however, 
significant equal magnitude reversal of morphine-induced hyperalgesia after injection of the 
MC1R antagonist MSG606, and not MK-801, was observed at 15 minutes post-injection (Figure 
2A).  This female-exclusive reversal resolved within the one-hour testing period.  No reversal of 
hyperalgesia was observed in either sex following injection of either control, indicating no effect 
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Figure 2A-B.  Time course of hyperalgesia in CD-1 females (2A) and males (2B) receiving 
continuous high-dose morphine infusion, as assessed by the tail-withdrawal test. Mice were 
implanted with NTX pellets (30 mg) on day -1, and implanted with morphine pumps containing 
a high dose of morphine (40 mg/kg/24h) on Day 0.  When hyperalgesic (day 4), mice were 
administered acute i.c.v. injections of one of the following: the NMDA receptor antagonist MK-
801 (.05mg/kg), the MC1R antagonist MSG606 (1.5 mg/ml), the MK-801 control, or the 
MSG606 control.  After which, all mice were assayed for nociception every 15 minutes for one 
hour.  Values represent mean tail-withdrawal latency ± S.E.M.; following antagonist injections at 
“0”, significant increases in withdrawal latencies relative to baseline values obtained on day 4 
are indicated (+), denoting significant reversal of hyperalgesia assessed at 15, 30, 45, and 60 







The major findings of Study 1 and Study 2 confirmed all hypotheses, and were as follows: 1) 
hyperalgesia in both male and female mice undergoing continuous low-dose morphine infusion 
is reversed exclusively by i.c.v injection of the NMDA receptor antagonist MK-801, but not the 
MC1R antagonist MSG606; 2) hyperalgesia resulting from continuous high-dose morphine 
infusion is reversed exclusively in males by the NMDA receptor antagonist MK-801, but 
reversed exclusively in females by i.c.v. injection of the MC1R antagonist MSG606. These two 
outcomes suggest that there are minimally two dose- and sex- dependent supraspinal 
mechanisms contributing to morphine-induced hyperalgesia.  These findings are discussed in 
detail below. 
 
Morphine-induced hyperalgesia is reversed by dose- and sex-dependent mechanisms 
specific to supraspinal loci.  Systemically administered opioids produce profound 
antinociceptive effects peripherally, supraspinally, and spinally, but the precise mechanism of 
action of the ensuing hyperalgesia is not as well understood (Jensen, 1997; Juni et al., 2008; Juni 
et al., 2010; Waxman et al., 2010).  In order to better classify the location of mechanisms 
modulating continuous morphine-induced hyperalgesia, the current study employed an 
intracerebroventricular receptor antagonist injection paradigm, intended to provide blockade of 
systems at exclusively supraspinal loci.  Our previous findings have shown there to be a 
systemically initiated sex- and dose-dependent mediation of morphine hyperalgesia, such that 
acute bolus injections of MK-801 or MSG606 reversed this state differentially in male and 
female mice (Juni et al., 2008; Juni et al., 2010).  For these reasons, the current studies also 




MSG606.  However, as our previous studies utilized systemic antagonist administration that 
allowed for widespread distribution throughout the peripheral and central nervous systems, it 
was unknown if the resulting reversal of hyperalgesia was modulated exclusively by supraspinal, 
spinal, or some combination of both central areas.  The results of the current study suggest that 
these hormone-dependent mechanisms are in fact regulated by supraspinal loci that function 
independently of ascending nociceptive input. 
 
While research examining the NMDA receptor system is at the forefront of study as a modulator 
of opioid induced hyperalgesia, the present data provide further evidence that this system is not 
entirely responsible for supraspinally-mediated MIH.  The NMDA receptor antagonist MK-801 
does not reverse hyperalgesia across the board, leaving hyperalgesia undisturbed in female CD-1 
mice receiving a high dose of morphine, corroborating our past studies (Juni et al., 2008; Juni et 
al., 2010).  The female-counterpart in the modulation of nociception is the melanocortin-1 
receptor, after it was discovered that the MC1R system appears to mediate κ-opioid analgesia 
exclusively in females. This is supported by the fact that κ-opioid receptor agonists are more 
efficacious in females than in males in clinical applications (Mogil et al., 2003; Mogil et al., 
2005).  Thus, the finding of a role for the MC1R in opioid analgesia led researchers to 
subsequently investigate a possible role of this receptor system in morphine-induced 
hyperalgesia.  As discussed in the General Introduction, Mogil and colleagues (2003) found the 
MC1R gene on chromosome 8 to be the most likely candidate gene to mediate states of female-
exclusive analgesia. This analgesia (induced by the κ-opioid agonist U50,488H)  is likely 




opioid’s analgesic state.  Thus, it is reasonable to postulate a supraspinally-mediated 
hyperalgesic mechanism involving this receptor system. 
 
Our recent findings (Juni et al., 2010) extend Mogil et al.’s (2003) rodent and clinical findings 
beyond κ-opioid analgesia to include morphine-induced hyperalgesia, such that both states are 
mediated by NMDA receptors in males and MC1Rs in females.  Taken together with the current 
finding that a sex- and dose- dependent state of morphine-induced hyperalgesia is differentially 
reversed specifically by i.c.v. injection of NMDAR and MC1R antagonists, it is likely that these 
hyperalgesic mechanisms are located supraspinally. NMDARs and MC1Rs are densely 
expressed throughout the brain and midbrain PAG, respectively (Renno, 1998; Juni et al., 2010; 
Gladding & Raymond, 2011; Swartjes et al., 2012; Xia, Wikberg, & Chhajlani, 1995; Mogil et 
al., 2005).  Noted, however, is the fact that both past and current findings are limited to high 
doses of morphine and that similar findings are not yielded by low morphine infusion doses, 
suggesting minimally two distinct dose-dependent supraspinal neural networks in the modulation 
of morphine-induced hyperalgesia. 
 
Morphine-induced hyperalgesia is, at least in part, regulated by supraspinal mechanisms.  
The current data suggest that opioid-induced hyperalgesia is regulated in a way that is similar to 
opioid analgesia, such that this sex- and dose- dependent phenomenon is mediated via 
supraspinal NMDA and MC1 receptor mechanisms.  However, the current study is limited to 
ventricular administration of the respective antagonists, which allows for distribution throughout 
the cortex; thus, the precise brain locus of action remains unknown.  More studies are needed to 




employed in the current study as stereotactic administration into precise cortical and subcortical 
areas are typically performed in rats, and our paradigms are limited to mice.  Likely candidates 
for more specific study are the PAG-RVM system, and the locus coeruleus (Heinricher, Tavares, 
Leith, & Lumb, 2009).  Specifically, more studies are needed to assess the role of PAG MC1Rs 
in morphine-induced hyperalgesia. 
 
The present study does not address the possibility that morphine-induced hyperalgesia may have 
independent supraspinal and spinal mechanisms, such that spinal loci could also mediate this 
nociceptive state on its own; however, we can now deduce that both areas are not collaboratively 
required to induce/maintain opioid-induced hyperalgesia.  The second study of this dissertation 






SPECIFIC AIM TWO: 
The contribution of spinal receptor sites to morphine-induced hyperalgesia 
 
1. INTRODUCTION 
While supraspinal sites such as the PAG and RVM are well-known associative areas involved in 
descending modulation of pain, the spinal cord is also thought to play a large role in this process.  
In fact, the RVM receives inputs from the dorsal horn of the spinal cord and additional rostral 
sites, and projects diffusely to both superficial and deep laminae of the dorsal horn (Zhuo & 
Gebhart, 1997).  Thus, the spinal cord is likely a critical site for the mediation of the 
antinociceptive effects of morphine (Akil et al., 1984; Basbaum & Fields, 1984; Yaksh, 1981).  
Specifically, opioid receptors densely populate laminae I, II, and III of the dorsal horn (the 
marginal zone, the substantia gelatinosa, and the nucleus proprius, respectively), as well as 
dorsal root ganglia in the spinal cord (Quirion, 1984; Gouardères et al., 1985).  These outer 
laminae are the principal spinal sites of action of morphine’s nociceptive signaling (Besse et al., 
1990). 
 
Giving further credence for a large role of the spinal cord in opioid processing, a study by 
Advokat and Burton (1987) demonstrated that in rats with transected spinal cords, the potency of 
systemically administered morphine was weakened in response to thermal nociceptive stimuli, 
while the potency of spinally administered morphine remained intact.  This suggests that opioids 
act directly on spinal sites to modulate nociceptive inputs, and that the loss of this spinal 
mechanism renders morphine nearly ineffective (Advokat & Burton, 1987).  Additionally, 
studies involving the blockade of spinal opioid receptors demonstrate to a marked reduction in 




bolus spinal injections of morphine for eight days developed thermal hyperalgesia, though 
associated with antinociceptive tolerance (Mao, et al., 1994).  In rats, continuous spinal delivery 
(via osmotic pumps) of DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin), a synthetic opioid 
peptide with high opioid receptor specificity/affinity also produced thermal hyperalgesia and 
tactile allodynia of the hind paws, accompanied by a decrease in analgesic potency and efficacy 
of spinal DAMGO (Vanderah, et al., 2000). 
 
Past literature documents dose-dependent effects of opioids in the spinal cord.  Specifically, both 
acute and chronic administration of high-dose opioids directly into the spinal cord produce a 
hyperalgesic response in both animals and humans (Sakurada, Komatsu, & Sakurada, 2005).  
Specifically, acute studies illustrate that high-dose morphine administration into the spinal 
subarachnoid space decreased tail-withdrawal latency, or induced hyperalgesia (Woolf, 1981).  
In rats implanted with continuous i.t. catheters, high-dose morphine yielded a series of pain 
behaviors such as biting and scratching, specifically at the dermatomes innervated by the spinal 
cord near the catheter tip (Yaksh & Harty, 1988; Yaksh, et al., 1986). Furthermore, pretreatment 
with NTX did not reduce these behaviors in studies employing similar paradigms (Sakurada, et 
al., 1996).  Serving as a striking counterpart to the Yaksh and colleagues (1986) study, a case 
report was described by Ali (1986) in which a patient with terminal cancer receiving high-dose 
spinal morphine demonstrated hyperalgesia in her lower extremities.  Subsequently, reports 
accumulated documenting hyperalgesic states in humans following administration of high-dose 
subarachnoid morphine (Arner, et al., 1988; De Conno, et al., 1991; Krames, et al., 1985; Penn & 





In contrast to high-dose morphine literature, there is conflicting evidence on low morphine doses 
administered via the spinal route.  Whereas some studies document that low-dose acute 
administration of the (-) morphine enantiomer produced significant analgesia, the (+) 
enantiomer, which is inactive at opioid receptor binding sites, produced hyperalgesia (Woolf, 
1981).  Other studies demonstrated that low-dose acute morphine produced brief excitatory 
effects in the flexor reflex, which is typically marked by the analgesic effect of morphine 
(Wiesenfeld-Hallin, et al., 1991). 
 
As previously mentioned, the most commonly proposed mechanism of MIH involves the 
colocalization of NMDA receptors and opioid receptors in the nervous system.  Of particular 
interest is that fact that both NMDA receptors and µ-opioid receptors are particularly abundant in 
lamina I-III of the dorsal horn (Mao et al., 2002; Gladding & Raymond, 2011).  It is 
hypothesized that opioids may somehow activate NMDA receptors. Specifically, Mao et al. 
(2002) report a downregulation of glutamate transporters in the spinal cord after several days of 
either acute injection or chronic infusion paradigms of morphine.  Interestingly, this reduction of 
GTs is not apparent until day six of morphine infusion and persists until minimally day eight, 
which partially corresponds with the manifestation of morphine hyperalgesia (Mao et al., 2002).  
Additional studies in mice and rats suggest that morphine-induced hyperalgesia is mediated by 
increased glutamate from primary afferent terminals in the dorsal horn of the spinal horn, and 
subsequent activation of NMDA receptors.  Moreover, several studies have suggested that an 
NMDA-NO cascade in the spinal cord may mediate this phenomenon (Watanabe, Okuda, et al., 
2003; Watanabe, Sakurada, et al., 2003).  Specifically, high-dose spinally administered morphine 




this increased generation of NO leads to increased activation of NMDA receptors in the spinal 
cord (Malmberg & Yaksh, 1993; Sorkin, 1993). 
 
Following our previous studies (Juni et al., 2008; Juni et al., 2010) combined with the results 
from Specific Aim 1, we also aimed to investigate the possible role of spinal MC1Rs.  While a 
supraspinal MC1R system is feasible due to this receptor’s distribution, particularly in the PAG, 
this receptor does not appear to have a widespread spinal presence (Xia, Wikberg, & Chhajlani, 
1995; Mogil et al., 2003).  Interestingly, a recent study reported the involvement of MC4R, a 
subtype diffusely distributed both supraspinally and spinally, in neuropathic pain.  Specifically, 
Delaney, Keighren, Fleetwood-Walker, and Jackson’s (2010) data suggest the involvement of 
more than one differentially distributed melanocortin receptor subtype in the modulation of 
female-specific pain.  
 
In addition to roles for NMDARs and MC1Rs, an upregulation of G-protein coupled NK-1 
receptors has been implicated in opioid-induced hyperalgesia.  Specifically, lamina I cells of the 
dorsal horn that express the NK-1 receptor have been shown to project to supraspinal areas that 
facilitate pain processing (Nichols et al., 1999). Additionally, paradigms involving substance P 
administration in mice either intermittently treated or continuously exposed to morphine also 
demonstrated greater c-Fos immunoreactivity in dorsal horn nuclei after morphine 
administration, presumably a result of substance P activity in these areas and indicative of 
neuronal sensitization.  This is supported by studies indicating that intrathecal morphine elicits 
substance P activity, increases spinal NK-1 receptor expression, and results in opioid-induced 




Clark, 2002; King et al., 2005).  Furthermore, the presence and activation of NK-1 receptors are 
crucial for the generation of activity-dependent LTP that requires a substance P-induced rise in 
Ca2+, likely involving Ca2+ release from intracellular stores, and a substance P-facilitated Ca2+ 
influx through NMDA receptors. This synaptic plasticity in spinal lamina I neurons has been 
shown to modulate hyperalgesia and may be augmented by the presence of opioids (Ikeda, et al., 
2003).  Finally, dynorphin (an endogenous peptide with significant non-opioid and NMDAR 
activity) evokes an array of self-injurious behaviors including persistent allodynia, and 
scratching, licking, and biting, conveniently mediated by NMDA receptors (Vanderah, et al., 
2000; Vanderah, et al., 1996).  It is suggested that opioids upregulate spinal dynorphin, which 
causes an increase of excitatory neurotransmitter release from primary afferent fibers.  This, in 
turn, promotes exaggerated pain through an NMDA-dependent mechanism (Gardell, et al., 2002; 
Vanderah, Suenaga, et al., 2001).  All of these aforementioned findings suggest a non-opioid 
receptor-mediated role of spinal NMDA receptors in opioid-induced hyperalgesia. 
 
Other studies have indicated that exposure to morphine mediated by intracellular protein kinase 
C (PKC) may prime NMDA receptors and cause increased excitability (Chen & Huang, 1992; 
Mao, Price, & Mayer, 1994; Martin, Malmberg, & Basbaum, 2001; Sluka & Audette, 2006). 
Interesting, most isoforms of the PKC enzyme are located in the outer layers of the dorsal horn, 
demonstrating an anatomical overlap of opioid receptors, NMDA receptors, and PKC activity 
(Sluka & Audette, 2006).  When activated in the spinal cord, PKC results in hyperalgesia on heat 
and mechanical assays, increased glutamate release, and sensitization of both dorsal horn 
neurons and the spinothalamic tract (Sluka & Audette, 2006).  Additionally, the development of 




inhibitor of PKC activity.  This illustrates a critical role for spinal activity of this protein that 
occurs in response to NMDA receptor activation in morphine-induced hyperalgesia (Mao et al., 
1994). 
 
The current study also uses morphine infusion pumps in mice pretreated with NTX pellets.  This 
protocol allows for investigation of the mechanisms involved in MIH not confounded by initial 
states of analgesia, and thus eliminates the possibility of opioid receptor involvement.  
Additionally, although morphine-induced hyperalgesia has been demonstrated in chronic 
paradigms that employ repeated injection (Ammon-Treiber & Hollt, 2005; Suzuki, Porreca, & 
Dickenson, 2006), as well as those using continuous infusion (Vanderah et al., 2001a; Xie et al., 
2005) protocols, it is believed that in the former context of discontinuous morphine delivery (i.e. 
multiple injections) hyperalgesia may be intensified by “mini withdrawal” episodes (Gutstein, 
1996; Angst et al., 2003; Ossipov et al., 2004).  As opioid withdrawal-induced hyperalgesia has 
been shown to be mechanistically distinct from the opioid-induced hyperalgesia currently under 
investigation (Harris et al., 2004; Dunbar et al., 2006), the use of osmotic pumps for morphine 
infusion eliminates the possible occurrence of withdrawal by providing uninterrupted, constant 
morphine exposure over several days. 
 
The goal of the present study is to further investigate spinal mechanisms underlying morphine-
induced hyperalgesia.  Accordingly, aforementioned findings (Juni et al., 2008; Juni et al., 2010) 
are subjected to replication with additional exploration of spinal involvement in the regulation of 
morphine hyperalgesia.  While there is documented research on the role of spinal NMDA 




spinal MC1 receptors in sex- and dose-dependent morphine hyperalgesia using antagonists of 
these receptor systems administered directly into the spinal cord via intrathecal injections.  As 
previous research has been limited to systemic administration (Juni et al. 2010), and the first 
series of studies in the current dissertation investigated supraspinal involvement, performing the 
current series of studies will allow us to further examine the neural networks specific to spinal 
loci that may be relevant to this hyperalgesic state.  We propose that at low doses of continuous 
morphine-induced hyperalgesia, this state will be reversed exclusively by spinal injection of the 
NMDAR antagonist, MK-801, in males and females.  At high doses of continuous morphine 
infusion, we believe that males will continue to use the NMDAR system to modulate morphine-
induced hyperalgesia. However, we are particularly interested in investigating the spinal 
pathways associated with the melanocortin-1 receptor, as the aforementioned literature on this 
receptor and its general neuronal network is scarce, suggesting minimal presence in spinal loci.  
The anatomy of this receptor system in the spinal cord as it relates to MSG606 is of particular 
interest, as we hypothesize that hyperalgesia elicited by high doses of morphine infusion in 
females may not be reversed by this antagonist. Findings yielded from the current studies 
combined with the findings from Specific Aim 1 will lead to our third series of investigations.  
Specifically, as there are distinct sex differences in continuous morphine-induced hyperalgesia, 




Adult male and female CD-1 mice (Charles Rivers, Kingston, NY), six to ten weeks of age, were 




light/dark cycle in a climate-controlled room (22 °C ± 2°C) with ad lib access to food (Purina 
chow) and filtered tap water.  Each subject was used once.  For all conditions, n ≥ 8. 
 
Nociceptive Assay 
The warm-water tail-withdrawal test, as described in detail above in the General Methods 
section, was chosen to assess nociception. This measure has repeatedly been shown to be stable 
and reliable in the context of recurrent testing (Elliott et al., 1995; Kest et al., 2002; Nemmani et 
al., 2004).   
 
Drug Delivery 
Twenty-four hours prior to initiation of morphine administration (labeled “day -1”), naltrexone 
(NTX) pellets were subcutaneously implanted.  One day later (labeled “day 0”), continuous 
morphine treatment of two distinct dosing paradigms was introduced via subcutaneous osmotic 
pump implantation. One group received a low dose of morphine (2mg/ml, yielding a cumulative 
dose of 1.6mg/kg/24h), whereas a second group received a high dose of morphine (50mg/ml, 
yielding a cumulative dose of 40mg/kg/24h).   When mice were rendered hyperalgesic (day 4), 
intrathecal injections of MSG606 (1.5 mg/ml), MK-801 (.05 mg/kg), the MSG606 control, or the 
MK-801 control were performed under oxygen/isoflurane inhalant anesthesia.  Intrathecal 
injections (2 µl volume) were performed under light oxygen/isoflurane inhalant anesthesia and 






Opioid-induced hyperalgesia was expressed as raw withdrawal latencies. Withdrawal latencies 
were analyzed using three-way analyses of variance (Sex * Antagonist Drug * Time) followed 
by a Fisher’s LSD (protected t-test) for post-hoc comparisons. P-values < 0.05 were considered 
significant. Data from low- and high-dose morphine studies were analyzed separately. 
 
3. RESULTS 
Study 3: Hyperalgesia in males and females during continuous low-dose morphine infusion 
All subjects were rendered significantly hyperalgesic on day 4 of continuous low-dose morphine 
administration (1.6 mg/kg/24h) after concomitant treatment with NTX, as assessed using the 
warm water tail-flick withdrawal assay.  Following a baseline measure on day 4, both males and 
females were injected via the i.t. route with an acute dose of either MSG606, MK-801, the 
MSG606 control, or the MK-801 control and tested every 15 minutes for one hour. 
 
Significant reversal of morphine-induced hyperalgesia after injection of the NMDA receptor 
antagonist MK-801 was already evident in both sexes at 15 minutes post-injection, and persisted 
throughout the entire one-hour testing period (Figure 3A-B).  However, no such effect was 
observed in males or females following injection of MSG606.  Additionally, no reversal of 
hyperalgesia was observed in either sex following injection of either control, indicating no effect 
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Figure 3A-B.  Time course of hyperalgesia in CD-1 females (3A) and males (3B) receiving 
continuous low-dose morphine infusion, as assessed by the tail-withdrawal test. Mice were 
implanted with NTX pellets (30 mg) on day -1, and implanted with morphine pumps containing 
a low dose of morphine (1.6 mg/kg/24h) on Day 0.  When hyperalgesic (day 4), mice were 
administered acute i.t. injections of one of the following: the NMDA receptor antagonist MK-
801 (.05mg/kg), the MC1R antagonist MSG606 (1.5 mg/ml), the MK-801 or MSG606 control.  
After which, all mice were assayed for nociception every 15 minutes for one hour.  Values 
represent mean tail-withdrawal latency ± S.E.M.; following antagonist injections at “0”, 
significant increases in withdrawal latencies relative to baseline values obtained on day 4 are 
indicated (+), denoting significant reversal of hyperalgesia assessed at 15, 30, 45, and 60 minutes 





Study 4: Hyperalgesia in males and females during continuous high-dose morphine infusion 
All subjects were rendered significantly hyperalgesic on day 4 of continuous high-dose morphine 
administration (40 mg/kg/24h) after concomitant treatment with NTX, as assessed using the 
warm water tail-flick withdrawal assay.  Following a baseline measure on day 4, both males and 
females were injected via the i.t. route with an acute dose of MSG606, MK-801, or the respective 
controls, and tested every 15 minutes for one hour. 
 
Significant reversal of morphine-induced hyperalgesia after i.t. injection of the NMDA receptor 
antagonist MK-801 was already evident in exclusively males at 15 minutes post-injection, and 
persisted throughout the entire one-hour testing period (Figure 4B).  In solely females, however, 
MSG606 did significantly reverse hyperalgesia (4A).  Finally, no reversal of hyperalgesia was 
observed in either sex following injection of either control, indicating no effect of the MSG606 
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Figure 4A-B.  Time course of hyperalgesia in CD-1 females (4A) and males (4B) receiving 
continuous high-dose morphine infusion, as assessed by the tail-withdrawal test. Mice were 
implanted with NTX pellets (30 mg) on day -1, and implanted with morphine pumps containing 
a high dose of morphine (40 mg/kg/24h) on Day 0.  When hyperalgesic (day 4), mice were 
administered acute i.t. injections of one of the following: the NMDA receptor antagonist MK-
801 (.05mg/kg), the MC1R antagonist MSG606 (1.5 mg/ml), the MK-801 control, or the 
MSG606 control.  After which, all mice were assayed for nociception every 15 minutes for one 
hour.  Values represent mean tail-withdrawal latency ± S.E.M.; following antagonist injections at 
“0”, significant increases in withdrawal latencies relative to baseline values obtained on day 4 
are indicated (+), denoting significant reversal of hyperalgesia assessed at 15, 30, 45, and 60 





Findings from Study 3 and Study 4 partially confirmed our hypotheses.  The major findings were 
as follows: 1) hyperalgesia in both male and female mice undergoing continuous low-dose 
morphine infusion is reversed exclusively by i.t. injection of the NMDA receptor antagonist MK-
801 but not the MC1R antagonist MSG606; 2) hyperalgesia resulting from continuous high-dose 
morphine infusion is reversed exclusively in males by the NMDA receptor antagonist MK-801; 
3) significant reversal of high-dose morphine-induced hyperalgesia is seen in exclusively 
females following i.t. administration of MSG606.  This third finding was surprising, in that 
spinal administration of MSG606 significantly reversed female hyperalgesia elicited by 
continuous infusion of high dose morphine.  These findings are discussed in detail below.   
 
Low dose morphine-induced hyperalgesia is reversed by the NMDAR system both 
supraspinally and spinally.  While systemically administered opioids produce profound 
antinociceptive effects peripherally, supraspinally, and spinally, the precise mechanism of action 
of the ensuing hyperalgesia is not as well understood (Jensen, 1997; Juni et al., 2008; Juni et al., 
2010; Waxman et al., 2010).  The studies of specific aim one provided support for the regulation 
of hyperalgesia by supraspinal mechanisms; however, the role of possible spinal mechanisms has 
remained inconclusive.  In order to better classify the location of the entirety of mechanisms 
modulating continuous morphine-induced hyperalgesia, the current study employed an 
intrathecal receptor antagonist injection paradigm.  Our previous findings have shown there to be 
a systemically and centrally initiated sex- and dose-dependent mediation of continuous 
morphine-induced hyperalgesia, such that both systemic injections (Juni et al., 2008; Juni et al., 




reversed this state differentially in male and female mice.  The current study therefore 
investigated the NMDA receptor antagonist MK-801 and the melanocortin-1 receptor antagonist 
MSG606, administered intrathecally.  As our previous studies utilized systemic antagonist 
administration that allowed for widespread distribution throughout the peripheral and central 
nervous systems, it was unknown if the resulting reversal of hyperalgesia was modulated 
exclusively by supraspinal, spinal, or some combination of both central areas.  According the 
results of the current dissertation, it appears that in males, and females at exclusively low doses 
of morphine, both supraspinal and spinal NMDARs play a role in morphine-induced 
hyperalgesia.  
 
High dose morphine-induced hyperalgesia is reversed by dose-, sex-, but not location-
dependent mechanisms.  The results of the current study suggest that the hormone-dependent 
mechanisms of morphine-induced hyperalgesia are regulated independently in the brain and 
spinal cord.  That is, at low doses of continuous morphine administration, NMDAR antagonism 
at the spinal level reverses hyperalgesia in both male and female mice.   However, continuous 
high doses of morphine yield different results.  Specifically, it appears that at high morphine 
doses, spinally regulated NMDAR antagonism remains sufficient for male mice in the reversal of 
this hyperalgesic state.  Conversely, female mice undergo significant hyperalgesic reversal by 
spinally administered MSG606 following continuous administration of high morphine doses.  
Although not typical of quickly-absorbed lipophilic compounds such as morphine, it is possible 
for compounds to spread rostrally after spinal administration, making their way to the brain via 
cerebrospinal fluid.  However, the dispersal of the 2 µl-injection volume used in these studies has 




some time for an intrathecally-injected compound to exert an effect via action in the brain.  
Additionally, by the time rostral spread to the brain occurs, several half-lives of the drug would 
have passed, making for a much weaker or nonexistent drug concentration (Rossi, unpublished 
data and observations). Thus, we report that in addition to a hyperalgesic neural network in the 
brain, there exists a spinal locus that independently regulates morphine-induced hyperalgesia.  
That is, while the NMDAR mechanism that regulates hyperalgesia appears to be present and 
undoubtedly functional in the spinal cord, the current evidence suggests that the female-typical 
MC1R system also appears to be present in functionally significant concentrations beyond 
supraspinal loci.  This provides contradictory evidence for reports that MC1Rs are found in 
dense concentrations in the PAG, and are not widespread in the spinal cord (Xia, Wikberg, and 
Chhajlani, 1995; Delaney et al., 2010).  Indeed, it appears that MC1Rs are present in functionally 
significant concentrations in the spinal cord as well as the brain.  However, much more research 
is needed to corroborate these findings and speculations. 
 
In attempt to further define these sex-dependent mechanisms underlying morphine-induced 
hyperalgesia, the third series of studies in this dissertation replicates the first two series, with the 





SPECIFIC AIM THREE: 




While the NMDA receptor system was the first to demonstrate promise in terms of regulating 
morphine induced hyperalgesia, it is now known that this system is not entirely responsible for 
this phenomenon.  Previous literature documents that systemic administration of NDMA receptor 
antagonists reverses hyperalgesia in both males and females at a low dose, while it abolishes 
hyperalgesia exclusively in males at the high dose (Juni et al., 2008; Juni et al., 2010).  After 
ovariectomy (OVX), females resort to male-typical hyperalgesic patterns, suggesting that they 
possess the same systems but are diverted from using them only by circulating ovarian 
hormones.  This is further evidenced in that when ovariectomized females receive hormones via 
continuous estrogen replacement, their female-typical hyperalgesic patterns are restored.  
Therefore, it is believed that not only is there a role for NMDA receptor pathways in 
hyperalgesia, but also a hormonally regulated role for minimally a second receptor system in the 
MC1R system (Juni et al., 2008). 
 
While the MC1R system’s role in skin pigmentation and anti-inflammatory processes is well 
documented, this receptor system’s role in the inhibition and regulation of pain is not 
satisfactorily characterized.  In particular, this receptor system likely plays a role in hyperalgesia 
that is not clear.  This proposed function is conceivable, as MC1 receptors are found in the PAG.  
Coincidentally, it was a series of quantitative trait locus (QTL) mapping studies by Mogil et al. 




system.  Specifically, the MC1R system appears to mediate κ-opioid analgesia in females, but 
not males.  Mogil and colleagues (2003) used the highly selective κ-opioid receptor agonist 
U50,488H, in a study in which they found the MC1R gene on chromosome 8 to be the most 
likely gene to mediate female-specific analgesia.  Interestingly, clinical use of κ-opioid agonists 
is more efficacious in females when compared to males.  Additionally, it was reported that 
female analgesia was completely abolished after administration of the κ- opioid receptor 
antagonist nor-binaltorpimine, even though it was given two days prior to U50,488H injections.  
Finally, whereas MK-801 had no effect in mutant B6 female mice, mutant C57BL/6J-Mc1re/e 
mice (differentiated from B6 mice only by a lack of functional MC1Rs) demonstrated male-like, 
NMDA-mediated U50,488H analgesia.  Therefore, Mogil et al. (2003) concluded that B6 female 
mice are using the melanocortin system to mediate pain responses resulting from U50,488H 
administration.  In an interesting addition to this same series of studies, Mogil et al. (2003) 
blocked the MC1R system during U50,488H administration, using the antagonist Ac-Nle-Asp-
Trp-DPhe- Nle-Trp-Lys-NH2.  It was hypothesized that taking the MC1R system out of play 
would cause the mice to physiologically change the way they process pain, in that they would 
resort to using the NMDA receptor system when presented with a nonfunctional MC1R system.  
Indeed, this is precisely what occurred; U50,488H analgesia was potentiated in exclusively 
female mice following i.c.v. injection of the aforementioned antagonist, only to be reversed by 
injection of MK-801 (Mogil et al., 2003). 
 
With these aforementioned findings in mind, it is likely that if this system regulates sex-
differentiated analgesia, it also plays a role in sex-dependent hyperalgesia as well.  Recent 




findings, to now include morphine-induced hyperalgesia mediation by NMDA receptors in males 
and females following administration of low dose morphine, and exclusively MC1Rs in females 
proceeding high dose morphine treatment.  Specifically, these studies illustrated a sex difference 
in hyperalgesia, as female and male C57BL/6J (B6) naltrexone-pelleted mice showed 
hyperalgesia beginning on day 1 and 3, respectively, after continuous high dose morphine 
infusion.  However, only naltrexone-pelleted B6e/e male mice receiving a continuous infusion of 
high dose morphine were rendered hyperalgesia from Day 2 to 7 (Juni, et al. 2010). Furthermore, 
in mice undergoing continuous infusion of the high dose of morphine, MK-801 reversed 
hyperalgesia in B6 and CD-1 males but not in B6 or CD-1 females, while the selective MC1R 
antagonist MSG606 reversed hyperalgesia in exclusively B6 and CD-1 females.  Conversely, 
continuous infusion of a low dose of morphine caused hyperalgesia in both e/e males and 
females (Juni, et al. 2010), thus further suggesting the involvement of more than one neural 
substrate in sex-dependent morphine-induced hyperalgesia; specifically, both the NMDAR and 
MC1R systems.  This is further evidenced by aforementioned findings that although both male 
and female hyperalgesia is reversed by MK-801 after infusion of a low dose of morphine, female 
hyperalgesia begins later and lasts several infusion days, if not weeks, longer than males (Juni, et 
al. 2010, and unpublished observations). 
 
Together, these studies indicate that NMDA receptors mediate hyperalgesia during 
administration of low doses of morphine in male and female mice, whereas MC1Rs and NMDA 
receptors, respectively, play a role in female and male hyperalgesia during infusion of the high 
morphine dose.  Thus, this validates a critical role for the MC1R system in female MIH at some 




female opioid-induced hyperalgesia (Juni et al., 2010).  Additionally, the results of the first two 
series of studies in this dissertation not only replicate sex- and dose- dependent differences, but 
also further these findings by showing that these differences in morphine-induced hyperalgesia 
are regulated independently at supraspinal and spinal levels of the nervous system.  As such, 
further studies examining the role of ovarian hormones in this phenomenon are warranted.  Our 
past studies employed a paradigm in which ovariectomized mice were subjected to continuous 
estrogen replacement.  However, extended estradiol treatment can induce progesterone synthesis; 
thus, it is possible that our previous finding in which female-typical hyperalgesia was reinstated 
following continuous estrogen replacement is attributable to increased synthesis and presence of 
progesterone (Waxman et al., 2010).  Thus, in the current studies, ovariectomized females and 
intact males were subjected to acute progesterone replacement. 
 
In these studies, ovariectomized females and intact males were first subjected to identical 
treatment protocols as the first two series of studies.  The purpose was to first assess if 
ovariectomized females would resort to male-typical patterns of supraspinally and spinally 
regulated hyperalgesia during continuous morphine infusion.  An additional aim was to 
investigate these same ovariectomized females and intact males subjected to acute progesterone 
replacement in order to assess if female-typical patterns at both the supraspinal and spinal level 
could be reinstated or recruited, respectively.  We hypothesize that intact males will continue 
using the NMDAR system to modulate continuous morphine-induced hyperalgesia, and that 
removing circulating ovarian hormones in females will cause them to “switch” systems to mirror 
male patterns.  However, following acute subcutaneous progesterone replacement, we propose 




differences in morphine-induced hyperalgesia are a result of the presence of female hormones 
rather than a lack of male hormones, it is quite possible that progesterone administration in intact 




Adult male and female CD-1 mice (Charles Rivers, Kingston, NY), six to ten weeks of age, were 
housed 4 to a cage with same-sex littermates.  All mice were maintained on a 12:12-hour 
light/dark cycle in a climate-controlled room (22 °C ± 2°C) with ad lib access to food (Purina 
chow) and filtered tap water.  Each subject was used once.  For all conditions, n ≥ 8. 
Ovariectomy Surgical Procedures  
During surgery, female mice were subject to ovariectomy protocols, described in detail in the 
above General Methods section.  All mice were allowed to recover for 20 days before 
undergoing experimental protocols. 
Nociceptive Assay 
The warm-water tail-withdrawal test, as described in detail above in the General Methods 
section, was chosen to assess nociception. This measure has repeatedly been shown to be stable 
and reliable in the context of recurrent testing (Elliott et al., 1995; Kest et al., 2002; Nemmani et 





Continuous morphine of two distinct dosing paradigms was delivered via subcutaneous osmotic 
pump implantation. One group received a low dose of morphine (2mg/ml, yielding 
1.6mg/kg/24h), whereas a second group received a high dose of morphine (50mg/ml, yielding 
40mg/kg/24h). Naltrexone (NTX) pellets were subcutaneously implanted 24 h prior to pump 
implantation. Intracerebroventricular injections of MSG606, MK-801, DMSO + saline (MSG606 
vehicle control), or saline (MK-801) vehicle control were performed under oxygen/isoflurane 
inhalant anesthesia. MK-801 was dissolved in saline, while MSG606 was dissolved in a 10% 
DMSO vehicle.  Intrathecal injections of MSG606, MK-801, or their vehicles controls were 
performed under light oxygen/isoflurane inhalant anesthesia and administered by lumbar 
puncture.  Acute bolus injections of progesterone (0.0016mg/kg) were administered according to 
the formula of 10 ml for every kg of body weight. 
Testing Procedures 
In accordance with the first two series of studies in the current dissertation, both ovariectomized 
females and intact males receiving continuous low or high morphine infusion doses were 
subjected to either i.c.v. or i.t. antagonist injections on Day 4, and nociception was assessed for 
one hour post-antagonist injection.  On Day 6, all animals were subjected to identical procedures, 
with the addition of an acute subcutaneous injection of progesterone 30 minutes before 
antagonist injection. 
Data Analysis 
Opioid-induced hyperalgesia was expressed as raw withdrawal latencies. Withdrawal latencies 
were analyzed using three-way analyses of variance (Sex * Antagonist Drug * Time) followed 




significant. Data from low- and high-dose morphine studies were analyzed separately, as were 
i.c.v and i.t. studies. 
3. RESULTS 
Study 5: Hyperalgesia in intact males and ovariectomized females during continuous low-dose 
morphine infusion 
All subjects were rendered significantly hyperalgesic on day 4 of continuous low-dose morphine 
administration (1.6 mg/kg/24h) after concomitant treatment with NTX, as assessed using the 
warm water tail-flick withdrawal assay.  Following a baseline measure on day 4, both intact 
males and OVX females were injected via the i.c.v. route with an acute dose of either MSG606, 
MK-801, the MSG606 control, or MK-801 control, and tested every 15 minutes for one hour.  
Hyperalgesia was reinstated by Day 6 in all subjects; following a baseline measure on this day, 
both male and female mice received an acute s.c. injection of progesterone (0.0016mg/kg).  
Thirty minutes later, all subjects received an acute i.c.v. injection of MSG606, MK-801, or their 
respective controls.  All mice were tested every 15 minutes post-antagonist injection for one 
hour. 
 
Following continuous infusion of low morphine doses, intact females typically utilize the 
NMDAR system to mediate hyperalgesia; thus, OVX with subsequent progesterone replacement 
should not and did not cause a change in this pattern.  On day 4, significant reversal of morphine-
induced hyperalgesia after injection of the NMDA receptor antagonist MK-801 was already 
evident in both sexes at 15 minutes post-injection, and resolved within the one-hour testing 
period (Figure 5A-B). On Day 6, hyperalgesia in intact males and OVX females was reversed 




observed in males or females following injection of MSG606 on either testing day. Additionally, 
no effect was observed in either sex following injection of either control, indicating no influence 
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Figure 5A-B.  Time course of hyperalgesia in CD-1 females (5A) and males (5B) undergoing 
continuous low-dose morphine infusion, as assessed by the tail-withdrawal test. Mice were 
implanted with NTX pellets (30 mg) on day -1, and implanted with morphine pumps containing 
a low dose of morphine (1.6 mg/kg/24h) on Day 0.  When hyperalgesic (day 4), mice were 
administered acute i.c.v. injections of one of the following: the NMDA receptor antagonist MK-
801 (.05mg/kg), the MC1R antagonist MSG606 (1.5 mg/ml),  the MSG606 vehicle control, or 
MK-801 vehicle control.  After which, all mice were assayed for nociception every 15 minutes 
for one hour.  By Day 6, hyperalgesia was reinstated in all subjects.  Following a baseline 
measure on this day (0), all subjects received an acute s.c. injection of progesterone 
(0.0016mg/kg), followed by an acute i.c.v. injection 30 minutes later of MSG606, MK-801, or 
their respective controls.  All mice were tested every 15 minutes post-antagonist injection for one 
hour.  Values represent mean tail-withdrawal latency ± S.E.M.; following antagonist injections at 
“0”, significant increases in withdrawal latencies relative to baseline values obtained on Day 4 
and Day 6 are indicated (+), denoting significant reversal of hyperalgesia assessed at 15, 30, 45, 






Study 6: Hyperalgesia in intact males and ovariectomized females during continuous high-dose 
morphine infusion 
All subjects were rendered significantly hyperalgesic on day 4 of continuous high-dose morphine 
infusion (40mg/kg/24h) after concomitant treatment with NTX, as assessed using the warm 
water tail-flick withdrawal assay.  Following a baseline measure on day 4, both intact males and 
OVX females were injected via the i.c.v. route with an acute dose of either MSG606, MK-801, 
or the MSG606 or MK-801 control, and tested every 15 minutes for one hour.  On Day 6, 
hyperalgesia was reinstated in all subjects.  Following a baseline measure on this day, both male 
and female mice received an acute s.c. injection of progesterone (0.0016mg/kg).  Thirty minutes 
later, all subjects received an acute i.c.v. injection of MSG606, MK-801, and either the MSG606 
or MK-801 vehicle control.  All mice were tested every 15 minutes post-antagonist injection for 
one hour. 
 
Significant reversal of morphine-induced hyperalgesia after injection of the NMDA receptor 
antagonist MK-801 was already evident in males and OVX females at 15 minutes post-injection 
on day 4, and resolved completely within the one-hour testing period.  Following continuous 
infusion of a high morphine dose, intact females typically utilize the MC1R system to mediate 
hyperalgesia; thus, removal of circulating ovarian hormones via OVX should and did cause 
females to “switch” systems on day 4, using the NMDAR system.  However, subsequent 
progesterone replacement on day 6 caused females to resort back to their female-typical patterns, 
using the MC1R system to mediate their hyperalgesia.  However, females did appear to maintain 
use of the NMDAR system as well, although on a weaker scale than the MC1R system.  




female-typical system in males as well.  That is, intact males were able to use either a 
supraspinal NMDAR or MC1R system to mediate their high-dose morphine induced 
hyperalgesia.  However, reversal by the NMDAR system was significantly stronger than reversal 
by the MC1R system in males.  It is possible that a higher dose of progesterone may have had a 
more significant effect in both sexes lacking ovarian hormones.  No effect was observed in either 
sex following injection of either control, indicating no effect of the MSG606 or MK-801 vehicle 







Figure 6A-B.  Time course of hyperalgesia in CD-1 females (6A) and males (6B) receiving 
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implanted with NTX pellets (30 mg) on day -1, and implanted with morphine pumps containing 
a high dose of morphine (40 mg/kg/24h) on Day 0.  When hyperalgesic (day 4), mice were 
administered acute i.c.v. injections of one of the following: the NMDA receptor antagonist MK-
801 (.05mg/kg), the MC1R antagonist MSG606 (1.5 mg/ml),  the MSG606 vehicle control, or 
MK-801 vehicle control.  After which, all mice were assayed for nociception every 15 minutes 
for one hour.  By Day 6, hyperalgesia was reinstated in all subjects.  Following a baseline 
measure on this day (0), all subjects received an acute s.c. injection of progesterone 
(0.0016mg/kg), followed by an acute i.c.v. injection 30 minutes later of MSG606, MK-801, or 
their respective controls.  All mice were tested every 15 minutes post-antagonist injection for one 
hour.  Values represent mean tail-withdrawal latency ± S.E.M.; following antagonist injections at 
“0”, significant increases in withdrawal latencies relative to baseline values obtained on Day 4 
and Day 6 are indicated (+), denoting significant reversal of hyperalgesia assessed at 15, 30, 45, 





Study 7: Hyperalgesia in intact males and ovariectomized females during continuous low-dose 
morphine infusion 
All subjects were rendered significantly hyperalgesic on day 4 of continuous low-dose morphine 
infusion (1.6 mg/kg/24h) after concomitant treatment with NTX, as assessed using the warm 
water tail-flick withdrawal assay.  Following a baseline measure on day 4, both intact males and 
OVX females were injected via the i.t. route with an acute dose of MSG606, MK-801, or a 
MSG606 or MK-801 vehicle control and tested every 15 minutes for one hour.  Hyperalgesia 
was reinstated by Day 6 in all subjects; following a baseline measure on this day, both male and 
female mice received an acute s.c. injection of progesterone (0.0016mg/kg).  Thirty minutes 
later, all subjects received an acute i.t. injection of MSG606, MK-801, or their respective 
controls.  All mice were tested every 15 minutes post-antagonist injection for one hour. 
 
Significant reversal of morphine-induced hyperalgesia after injection of the NMDA receptor 
antagonist MK-801 was evident in both sexes at 15 minutes post-injection on day 4.  Following 
continuous infusion of a low morphine doses, intact females typically utilize the NMDAR 
system to mediate hyperalgesia; thus, OVX with subsequent progesterone replacement on day 6 
should not and did not cause a change in this pattern, as female hyperalgesia was mediated 
exclusively by the NMDAR system.  Additionally, progesterone on day 6 had no effect on males, 
as they also continued to use the NMDAR system to mediate hyperalgesia.  No effect was 
observed in males or females following injection of MSG606. Additionally, no effect was 
observed in either sex following injection of either control, indicating no effect of the MSG606 







Figure 7A-B.  Time course of hyperalgesia in CD-1 females (7A) and males (7B) receiving 
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implanted with NTX pellets (30 mg) on day -1, and implanted with morphine pumps containing 
a low dose of morphine (1.6 mg/kg/24h) on Day 0.  When hyperalgesic (day 4), mice were 
administered acute i.t. injections of one of the following: the NMDA receptor antagonist MK-
801 (.05mg/kg), the MC1R antagonist MSG606 (1.5 mg/ml),  a MSG606 vehicle control, or a 
MK-801 vehicle control.  After which, all mice were assayed for nociception every 15 minutes 
for one hour.  By Day 6, hyperalgesia was reinstated in all subjects.  Following a baseline 
measure on this day (0), all subjects received an acute s.c. injection of progesterone 
(0.0016mg/kg), followed by an acute i.t. injection 30 minutes later of MSG606, MK-801, or their 
respective controls.  All mice were tested every 15 minutes post-antagonist injection for one 
hour.  Values represent mean tail-withdrawal latency ± S.E.M.; following antagonist injections at 
“0”, significant increases in withdrawal latencies relative to baseline values obtained on Day 4 
and Day 6 are indicated (+), denoting significant reversal of hyperalgesia assessed at 15, 30, 45, 




Study 8: Hyperalgesia in intact males and ovariectomized females during continuous high-dose 
morphine infusion 
All subjects were rendered significantly hyperalgesic on day 4 of continuous high-dose morphine 
administration (40 mg/kg/24h) after concomitant treatment with NTX, as assessed using the 
warm water tail-flick withdrawal assay.  Following a baseline measure on day 4, both intact 
males and OVX females were injected via the i.t. route with an acute dose of either MSG606, 
MK-801, a MSG606 vehicle control, or a MK-801 vehicle control, and tested every 15 minutes 
for one hour.  Hyperalgesia was reinstated by Day 6 in all subjects; following a baseline measure 
on this day, both male and female mice received an acute s.c. injection of progesterone 
(0.0016mg/kg).  Thirty minutes later, all subjects received an acute i.t. injection of MSG606, 
MK-801, or their respective controls.  All mice were tested every 15 minutes post-antagonist 
injection for one hour. 
 
On day 4, significant reversal of morphine-induced hyperalgesia after injection of the NMDA 
receptor antagonist MK-801 was evident in both sexes at 15 minutes post-injection.  However, 
progesterone replacement on day 6 in exclusively OVX female mice allowed the recruitment of 
both the NMDAR and the MC1R system, while males continued to recruit exclusively the 
NMDAR system.  No effect was observed in either sex following injection of either control, 
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Figure 8A-B.  Time course of hyperalgesia in CD-1 females (8A) and males (8B) receiving 
continuous high-dose morphine infusion, as assessed by the tail-withdrawal test. Mice were 
implanted with NTX pellets (30 mg) on day -1, and implanted with morphine pumps containing 
a high dose of morphine (40 mg/kg/24h) on Day 0.  When hyperalgesic (day 4), mice were 
administered acute i.t. injections of one of the following: the NMDA receptor antagonist MK-
801 (.05mg/kg), the MC1R antagonist MSG606 (1.5 mg/ml),  a DMSO + saline vehicle control, 
or a saline vehicle control.  After which, all mice were assayed for nociception every 15 minutes 
for one hour.  By Day 6, hyperalgesia was reinstated in all subjects.  Following a baseline 
measure on this day (0), all subjects received an acute s.c. injection of progesterone 
(0.0016mg/kg), and an acute i.t. injection 30 minutes later of either MSG606, MK-801, a 
MSG606 vehicle control, or a MK-801 vehicle control.  All mice were tested every 15 minutes 
post-antagonist injection for one hour.  Values represent mean tail-withdrawal latency ± S.E.M.; 
following antagonist injections at “0”, significant increases in withdrawal latencies relative to 
baseline values obtained on Day 4 and Day 6 are indicated (+), denoting significant reversal of 
hyperalgesia assessed at 15, 30, 45, and 60 minutes post-injection.  Where apparent, significant 







Studies 5, 6, 7, and 8, while almost entirely confirming our hypotheses, yielded interesting 
findings.  The major findings of these studies were as follows: 1) at low doses of continuous 
morphine infusion, supraspinal NMDA, but not MC1, receptor blockade reverses hyperalgesia in 
male and OVX female mice, and this sensitivity to NMDA receptor blockade is unchanged by 
progesterone administration in either sex; 2) at high doses of continuous morphine infusion, 
supraspinal NMDA receptor, but not MC1R, blockade reverses hyperalgesia in both males and 
OVX females; 3) following progesterone administration in these same mice, OVX females and 
intact males are able to recruit the use of both MC1R and NMDAR systems; however, the effect 
of the MC1R- or NMDAR-regulated reversal is more robust in OVX females or intact males, 
respectively; 4) at low doses of continuous morphine infusion, male and OVX female mice 
recruit a spinal NMDAR system to modulate hyperalgesia, and progesterone replacement in 
these same animals leaves these patterns undisturbed; 5) at high doses of continuous morphine 
infusion, potent reversal by exclusively a spinal NMDAR system is evident in both males and 
OVX females; 6) following progesterone administration in these same mice, exclusively OVX 
females are able to recruit the use of both NMDAR and MC1R systems to mediate hyperalgesic 
reversal of similar magnitude.  Unexpected was the finding that progesterone administration in 
males elicited female-typical patterns following the specific treatment paradigm of high dose 
morphine treatment paired with i.c.v. antagonist injections, but not i.t. antagonist injections.  
Additionally, while not surprising following speculation, we had not considered that 
progesterone-exposed OVX females would retain the use of both NMDAR and MC1R systems 
following high dose morphine treatment.  Specifically, we hypothesized that intact female-




outcomes suggest that female ovarian hormones play a major role in the modulation of 
morphine-induced hyperalgesia. These findings are discussed in detail below. 
 
Female hormones play a large role in mediated morphine-induced hyperalgesia. Our 
previous findings have shown there to be a systemically and centrally initiated sex- and dose-
dependent mediation of continuous morphine-induced hyperalgesia, such that both systemic 
injections (Juni et al., 2008; Juni et al., 2010) and central injections (the current dissertation) of 
MK-801 or MSG606 reversed this state differentially in male and female mice.  The previous 
studies of this dissertation illustrated that both supraspinal and spinal mechanisms are involved 
in morphine-induced hyperalgesia.  The current study therefore investigated the role of female 
hormones in recruiting supraspinal and spinal NMDAR and MC1R systems in the mediation of 
morphine-induced hyperalgesia. The results of the current series of studies provide support for 
the notion that, not only are circulating ovarian hormones responsible for the switch between the 
NMDAR and MC1R system, but that these mechanisms work independently in both supraspinal 
and spinal loci.  Interestingly, it is often reported that females demonstrate lower pain thresholds 
and largely represent those suffering from unremitting pain (Mogil, 2012); such clinical findings 
in conjunction with the current findings suggest that females are predisposed to the use of a dose-
dependent hyperalgesic mechanism that is influenced by ovarian hormones.  While what 
precisely cause females to have lower pain thresholds remains unknown, further investigation 
into the role of hormones in clinical studies is warranted. 
 
Previous findings on the relationship between gonadal hormones and endogenous pain control 




estrogen receptors) and opioid receptors are co-localized on peripheral sensory neurons and 
neurons in the central nervous system.  Research has shown that the endogenous opioid system is 
modulated in part by estrogen and testosterone; that estradiol causes µ-receptor internalization 
(Wiesenfeld-Hallin, 2005; Aloisi, Della Seta, Rendo, Ceccarelli, Scaramuzzino, et al., 2002).  
Interestingly, it is hypothesized that the sex differences seen in pain perception are in part due to 
increased activity of the endogenous opioid receptor system in males when compared to females.  
Investigations used mice lacking a subunit of the G-protein-coupled inwardly rectifying 
potassium receptor (GIRK); this particular channel has an important role in a neuron’s response 
to analgesics acting through all three opioid-GPCRs.  Specifically, Mitrovic, Margeta-Mitrovic, 
Bader, Stoffel, Jan, et al. (2003) found that male mice are less sensitive to thermal nociception 
than are females.  However, in GIRK2 knock-out mice this sex difference is no longer apparent, 
as male thresholds were reduced to that of females.  Additionally, whereas male mice 
demonstrate stronger morphine-induced analgesia than females, this sex difference was also 
abolished in mice lacking GIRK2; however, the overall analgesic effect of morphine was also 
reduced.  However, a major problem with the extrapolation of these findings lies in that humans 
tend to exhibit reverse patterns; that is, females typically exhibit stronger µ- and κ- receptor 
mediated analgesia than males in clinical populations.  In fact, in studies on postoperative opioid 
consumption, women tend to consume less than half the amount of opioids that men do, 
suggesting a superior opioid analgesic effect in women.  A second issue lies in the fact that 
women demonstrate varying pain thresholds depending of the follicular phase of their menstrual 
cycle (Wiesenfeld-Hallin, 2005).  Nonetheless, it is not entirely known how sex differences in 
opioid-induced hyperalgesia are mediated, and these data suggest that hormones may a major 





Administration of female hormones allows males to recruit supraspinal female-typical 
hyperalgesic mechanisms. The current data suggest that the female-typical mechanism of 
hyperalgesia is located supraspinally and spinally.  It is interesting that in those current studies 
that investigated exclusively supraspinal mechanisms in intact male and OVX female mice, 
findings that supported specific aim 1 and 2 were discovered.  That is, both male and OVX 
female mice recruited powerful supraspinal-level NMDAR systems during infusion of both 
doses of morphine.  However, progesterone caused both cohorts to recruit powerful NMDAR 
and MC1R supraspinal systems to mediate hyperalgesia.  At low doses of morphine infusion, 
males and OVX females continue to use a powerful spinal NMDAR-modulated hyperalgesic 
mechanism across the board.  At high doses of continuous morphine, males and OVX females 
use the NMDAR system; however, following progesterone replacement, spinally administered 
MSG606 has no effect on males, yet evokes a significant effect in females.  This supports the 
findings from specific aim 2; that there does appear to be a functional hyperalgesic mechanism in 
the spinal cord that involves the MC1R system.  However, why males only recruit a supraspinal 
MC1R system after progesterone injection (Study 6) and not a spinal mechanism as well (Study 






I. GENERAL DISCUSSION 
 
The overall aim of the current dissertation was to elucidate the precise location(s) of action of the 
regulatory mechanisms that underlie morphine-induced hyperalgesia.  The current studies 
demonstrate several findings that expand upon what is currently known about this phenomenon:  
1) Continuous low dose morphine-induced hyperalgesia is reversed by i.c.v. administration of 
the NMDAR antagonist MK-801 in both males and females;  2) continuous high dose morphine-
induced hyperalgesia is reversed by i.c.v. administration of MK-801 in exclusively males;  3) 
This same continuous high dose morphine-induced hyperalgesia is reversed exclusively by i.c.v. 
administration of the MC1R antagonist MSG606 in females only;  4) continuous low dose 
morphine-induced hyperalgesia is reversed by i.t. administration of the NMDAR antagonist MK-
801 in both males and females;  5) continuous high dose morphine-induced hyperalgesia is 
reversed by i.t. administration of MK-801 in exclusively males;  6) This same continuous high 
dose morphine-induced hyperalgesia is significantly reduced by i.t. administration of the MC1R 
antagonist MSG606 in females only;  7) Following ovariectomy, females exhibit male-typical 
patterns of hyperalgesia at both high and low doses of continuous morphine administration;  8) 
After an acute injection of systemic progesterone, female typical patterns of hyperalgesia are 
restored following i.c.v. antagonist administration;  9) Following an acute injection of systemic 
progesterone, there appears a spinal MC1R mechanism that modulates female-typical high dose 
morphine-induced hyperalgesia; 10) Following progesterone replacement, males are capable of 





There are several limitations to the studies detailed within this dissertation.  All assessments 
were conducted using morphine, a substance that preferentially binds to the µ opioid receptor, a 
characteristic common to virtually all opioids reported to cause hyperalgesia in humans and 
rodents (Xu et al., 2003; Ossipov et al., 2004).  While the current studies provide evidence for 
how these opioids cause hyperalgesia independently of opioid receptor activity, these findings 
are novel and thus we cannot say with utmost certainty if these assumptions can be extrapolated 
to include delta and kappa receptor opioids, or even other µ-preferring opioids administered 
under other paradigms (Mogil, 2012).  Further studies that assess the hyperalgesic tendencies of 
different opioids are required before such comparisons can be made.  Furthermore, since the 
dependent nociceptive measure in all studies described in this dissertation, the tail withdrawal 
test, is a measure of thermal reflexive pain, it is possible that different results would be obtained 
on other nociceptive measures such as mechanical or chemical pain (Mogil et al., 1999a, 1999b, 
Mogil, 2012).  Another issue is the possibility that spinally administered antagonists exerted their 
effects following rostral spread; in other words, it is possible that these substances travelled to 
the brain to exert their effects.  While morphine is absorbed into the bloodstream of the spinal 
cord quickly and likely doesn’t spread beyond the spinal cord, it is unknown if MK-801 or 
MSG606 undergo rostral spread.  However, the dispersal of the 2 µl-injection volume used in 
these studies has been observed to travel approximately 0.5 to 1cm within 30 minutes.  Thus, it 
would take quite some time for an intrathecally-injected compound to exert a supraspinal effect.  
Additionally, by the time rostral spread to the brain occurs, it is likely that several half-lives of 
the drug would have passed, making for a much weaker or nonexistent drug concentration 
(Rossi, unpublished data and observations).  Finally, only outbred CD-1 mice were used as 




1999; Waxman, 2012). Thus, applicability beyond the narrow conditions described above should 
not be assumed. 
 
In attempt to further characterize this dose- and sex- dependent paradoxical state, the current 
dissertation employed several paradigms to demonstrate that hyperalgesia may be mediated in a 
location-dependent manner as well.  Previous continuous morphine infusion studies using 
receptor blockade to investigate the mechanisms involved in hyperalgesia employed systemic 
injections, which allows for widespread distribution throughout the peripheral and central 
nervous system and thus does not specify the precise central locus of action (Juni et al, 2008; 
Juni et al., 2010).  The current dissertation employed a central paradigm of antagonist 
administration.  Specifically, the role of supraspinal and spinal NMDAR and MC1R systems 
were investigated.  It appears that at the supraspinal level, there exists a powerful NMDAR 
mechanism that modulates both male and female hyperalgesia as low doses of morphine 
infusion.  However, while males continue to employ the NMDAR system at high doses of 
morphine infusion, females recruit a powerful supraspinal MC1R system. 
 
In terms of spinal loci, it appears that there is a prevalent NMDAR mechanism that can 
independently regulate morphine hyperalgesia in males, and females at exclusively low doses of 
morphine infusion.  Additionally, hyperalgesia following high dose morphine infusion in females 
is significantly regulated by a spinal MC1R mechanism, such that blockade of this receptor 
system resulted in hyperalgesic reversal.  Thus, we hypothesize that while females possess a 
spinal male-typical NMDAR system, they also employ the use of a MC1R system to regulate 




spinal cord, the current data suggest otherwise.  Molecular and biochemical studies detailing 
MC1R distribution in the spinal cord are needed to corroborate these findings. 
 
The current studies are intriguing when compared to previous studies reporting equivalent 
qualitative sex differences in opioid analgesia.  Specifically, NMDA receptor antagonists have 
been shown to reduce kappa opioid analgesia in male but not female mice (Kavaliers & Choleris, 
1997).  In male mice, spinally regulated analgesia has been shown to require the activation of 
exclusively the µ-opioid receptor, while females require the use of both mu- and κ-opioid 
receptors and the subsequent production of spinal dynorphin in order to experience the same 
magnitude of analgesia.  Thus, it is apparent that sex differences are mediated by the presence of 
ovarian hormones in females (Liu, von, & Gintzler, 2007).  Likewise, numerous studies have 
reported that κ-opioid receptor compounds utilize different physiological circuitry in males and 
females (Sternberg, Ritchie, & Mogil, 2004; Holtman, Jr. & Wala, 2006; Lomas, Barrett, Terner, 
Lysle, & Picker, 2007; Mogil, 2012), leading κ-agonists to be significantly more effective 
analgesic agents in both rodent and human females (Miller & Ernst, 2004; Mogil et al., 2005).  
This study extends the current findings to analgesia; that MK-801 effectively augments analgesia 
in OVX females, while OVX followed by estrogen injection reinstates the MK-801 insensitivity 
characteristic of intact females.  Based on these findings, the authors concluded that estrogen 
diverts pain modulation in females towards a system that functions independently of the 
NMDAR system characteristic of males. 
 
While a comprehensive understanding of the mechanisms underlying morphine-induced 




important findings in terms of sex differences in morphine-induced hyperalgesia.  As suggested 
by its susceptibility to NMDA receptor antagonism, typical morphine-induced hyperalgesia in 
males (but not intact females) is under the influence of exclusively NMDA receptors.  Thus, it is 
practical that others report greater increases in morphine analgesia in male mice following MK-
801 administration relative to females (Lipa & Kavaliers, 1990).  Moreover, the failure of MK-
801 to reverse hyperalgesia in females across the board, and the ability for i.c.v. MSG606 to 
reverse male hyperalgesia following progesterone administration provides additional support 
favoring the existence of supraspinal sex-specific hyperalgesic mechanisms.  Interestingly, the 
current studies demonstrate that if males are given female hormones, they have the ability to 
recruit an exclusively supraspinal female-typical hyperalgesic mechanism.  Conversely, males do 
not appear to recruit a spinal MC1R system after progesterone administration.  It appears as 
though in such a case, the spinal NMDAR is superior. 
 
While the current studies further define morphine hyperalgesia during continuous infusion, the 
mechanisms underlying this paradoxical state still remain unclear.  In particular, the current 
dissertation suggests a more complicated sex-dependent mechanism, in that males may also 
recruit female-typical systems while still producing their own gonadal hormones.  Interestingly, 
both male castration and the administration of gonadal hormones in OVX females decrease the 
potency of morphine-induced analgesia, suggesting that male hormones increase the efficacy of 
opioid analgesics (Bodnar and Kest, 2009).  Thus, one could speculate that the lack of male 
hormones in females leaves them more susceptible to morphine-induced hyperalgesia.  There are 
many studies that document sex differences in the clinical perception of pain, but while these 




hormonally disadvantageous pain processing system.  
 
While a supraspinal MC1R system is feasible due to this receptor’s distribution in the PAG and 
in brain-glial cells (which more recently are speculated to play a role in hyperalgesia), this 
receptor is not reported to have widespread spinal distribution (Xia, Wikberg, & Chhajlani, 1995; 
Mogil et al., 2003).  Unfortunately, most of the research concerning this receptor system 
investigates its role in hair and skin pigmentation, and other skin-related variables.  Most of the 
research that exists on the role of the MC1R in pain relates to its action in antinociception, as 
detailed above.  Thus, not much is known beyond the expanded findings of this dissertation in 
terms of how the MC1R regulates female-typical hyperalgesia.  Interestingly, a recent study 
reported the involvement of MC4R, a subtype diffusely distributed both supraspinally and 
spinally, in neuropathic pain.  Specifically, Delaney et al. (2010) found an upregulation of the 
fourth melanocortin subtype specifically in the spinal cord in response to peripheral nerve injury.  
While this type of pain sensitivity is not identical to morphine-induced hyperalgesia, these 
findings suggest the involvement of more than one differentially distributed melanocortin 
receptor subtype in the modulation of female-specific pain.  Future research must investigate 
differential processes of all five of the MC receptor subtypes, particularly the relationship 
between the MC1R and MC4R.  It is possible that spinal MC4Rs may serve as a counterpart to 
supraspinal MC1Rs, mediating neuropathic pain and hyperalgesia, respectively.  Finally, more 
studies that detail the distribution of the MC1R, particularly in the spinal cord, are imperative.  
As suggested by the current studies, there appears to be both a supraspinal and spinal MC1R 
system that modulates pain processing.  Specifically, as MC1Rs, opioid receptors, and estrogen 




opioids, their proposed hyperalgesic mechanisms, and the gonadal steroid hormones that 
determine these effects. While this site is already known to play a role in pain inhibition, 
corroborative studies detailing its role in pain facilitation are needed (Bodnar and Kest, 2009).  
As no such spinal locus is immediately evident, related future studies could detail the existence 
of a spinal female MC1R pain processing system.   
 
Research on general sex differences in pain, both preclinically and clinically, a consensus is not 
immediately evident.  While there is a vast amount of animal studies that investigate pain, most 
paradigms use exclusively males in their studies.  Ironically, females are often excluded due to 
the very issue that causes their sex-differentiated pain: fluctuations in ovarian hormones.  
Because of their exclusion, this leaves the important area of female-typical pain unaddressed.  
For instance, the phase of the estrous cycle appears to play a role in animal models of female-
mediated analgesia; specifically, systemically initiated analgesia is most potent during the 
metestrus and proestrus phases, and least effective during the estrous phase (Mogil, 2012; 
Terner, Lomas, and Picker, 2005; Bodnar and Kest, 2009).  In humans, females tend to have 
higher pain tolerance during the follicular phase (Mogil, 2012).  Additionally, preclinical 
literature suggesting superior analgesic effect in women following treatment with κ-agonists 
extrapolates to the clinical population.  Thus, pharmacokinetic and pharmacodynamic sex 
differences are likely also at play, and it is likely that these hormone fluctuations play a role in 
hyperalgesia. 
 
While many of the sex differences seen in pain research are detailed above as quantitative 




treatment for unremitting pain.  Secondly, women could be more susceptible to these chronic 
pain syndromes (likely due to hormonal cyclicity).  Finally, it is possible that women 
demonstrate lower pain thresholds than men, due to variations in descending and ascending pain 
transmission pathways, or genetic variations.  While all of these hypotheses present valid 
arguments, the only trend that unanimously holds up to the rigors of methodical scientific 
research is that women show reduced pain thresholds and increased pain sensitivity when 
compared to men (Mogil, 2012).  Thus, the current dissertation suggests a hormonal mechanism 
by which women may demonstrate inferior pain processing.  While the current studies by no 
means advocate for a reduction in the use of opioids in clinical settings, our findings shed a 
brighter light on sex differences in pain processing.  Although there is an overwhelming amount 
of research on sex differences in pain, the clinical impact remains inadequate.  As chronic pain is 
an increasingly growing issue that overwhelmingly encompasses the woman patient, it is 






GLOSSARY OF ABBREVIATED TERMS 
α-MSH: α-melanocyte-stimulating hormone 
AMPA: α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ACTH: adrenocorticotrophin 
β-FNA: β-funaltrexamine 
BBB: blood brain barrier 
BL: baseline 
cAMP-PDE: cyclic adenosine monophosphate phosphodiesterase 
C: degrees Celsius 
CCK: cholecystokinin 
cm: centimeters 
CTX-B: cholera toxin B-subunit 
DMSO: dimethyl sulfoxide 
DRG: dorsal root ganglia 
GABA: γ-aminobutyric acid 
GIRK2: second subunit of the G-protein-coupled inwardly rectifying potassium receptor 














MC1R: melanocortin-1 receptor subunit 
MC4R: melanocortin-4 receptor subunit 
MIH: morphine-induced hyperalgesia 
Mrp3: multidrug resistance protein 3 
NMDA: N-methyl-D-aspartate 




NO: Nitric oxide 
Nor-BNI: norbinaltorphimine 
OIH: opioid-induced hyperalgesia 
ORL1: opioid receptor-like type receptor 
OVX: ovariectomy 




PKC: protein kinase C 
PSD: post-synaptic density 
QMWS: quasi-morphine withdrawal syndrome 
QTL: quantitative trait loci 
RVM: rostral ventromedial medulla 
s: seconds 
s.c.: subcutaneous 
TLR4: toll-like receptor subtype 4 
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